



# PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

## WELCOME

Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure  
Olivier COUX, Chair, ProteoCure  
Cris RAJO, Grant Holder Manager, ProteoCure



# PROTEOCURE

# ProteoCure Cost Action Network Opportunities for Funding and Collaboration

October 30, 2023 10:00 – 12:30 hours





## AGENDA

10.00 h (5')	Welcome	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure Olivier COUX, Chair, ProteoCure Cris RAJO, Grant Holder Manager, ProteoCure
10.05 – 10.50 h (45')	Funding Opportunities for Health Research under Horizon Europe	Marina MARTINEZ, Horizon Europe Programme Officer, CDTI SOST-Brussels, Directorate of European Programmes and Regional Cooperation
10.50 – 11.30 h (40')	Success experiences from participation in EU-projects	Rune MATTHIESEN, WG2 Leader, ProteoCure. Coordinator of EVCA, European Call Twinning 2020 Rosa BARRIO, Grant Awarding Coordinator, ProteoCure. Coordinator of COST Proteostasis and UPSTREAM, ITN program Manuel S. RODRIGUEZ, Science communication co-leader, ProteoCure, Coordinator of ubiCODE, Marie Skłodowska-Curie Actions Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project, HORIZON.2.1 - Health Olivier COUX, Chair, ProteoCure
11.30 – 12.20 h (50')	Get your Project Funded! - Working Group for ProteoCure funding proposals	All attendees
12.20 – 12.30 h (10')	Closing Remarks & Future Actions	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure COST Action Olivier COUX, Chair, ProteoCure COST Action

# PRACTICAL ISSUES

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours






## How do you see the role of European projects in your research/innovation activities in the future?

● Essential	80
● Important but not essential	40
● Not important	3

65% of you consider the role of European projects to be essential for your future activities and 30% view them as very important although not essential, with only 3% not considering them relevant at all.


These results show that the role of European projects is of high importance to 95% of you







# How do you consider your current funding status?





# Are you likely to apply for Horizon Europe funding in the future?

62%  
Yes




33%  
I am not sure / I do not know


4%  
No



# Are you planning to apply for an already identified European Call?



If you have replied Yes to the previous question, please specify the Call:






# Have you previously participated in any European projects? (Additional to the ProteoCure COST Action)



If you answered Yes to the above question, please specify the type of project(s) you participated:

- Research and Innovation Action ... 12
- Innovation Action (IA) 1
- Coordination and Support Actio... 4
- European Partnerships 16
- Marie Curie Postdoctoral Fellow... 28
- Doctoral Networks 24
- CoFund 6
- Doctoral Networks 24
- ERC 10
- Other (please specify) 27



If you answered 'Other' to the above question, please specify the type of project(s):

Research Council

Training Network innovative medicines Eurotech fellowship

Reintegration Grant Network innovative

Interreg POCTEFA EJP RDCOST **Cost Actions** ITN actions

Proteostasis COST NET Curie Marie ERA-NET

TRANSAUTOPHAGY COST Inco-Dev Neurodegenerative Diseases

Joint Programme



Are you open to collaborating with ProteoCure Members in the preparation of funding proposals?



87%  
Yes

12%  
No



Participation in a COST Action can significantly enhance **opportunities for collaboration in European funding proposals.**



By actively engaging in a COST Action, researchers can establish meaningful connections, **identify potential collaborators**, and build a **strong consortium.**

This collaborative environment fosters **the development of innovative ideas and joint research initiatives that can align with the priorities of European funding programs.**

Additionally, the insights gained from a COST Action can lead to a **deeper understanding of the European research landscape** and the **specific needs and challenges in various fields**, which is invaluable when crafting **competitive proposals.**



https://proteocure.eu



Home About News & Newsletters Calls Upcoming events Webinars Members Shared Documents Forum Jobs Videos Past Meetings Log In

**ProteoCure's Annual Meeting 2024**  
May 7th-10th, 2024

Hotel Mercure Warszawa Grand,  
WARSAW, Poland

STAY TUNED! →

**REGISTER**

**LOGIN**

# ProteoCure

**CONTACT**

A sound proteome for a sound body: targeting proteolysis for proteo

COST Action CA20113

## LOGIN

Login Forgot Password

**User Name**  
User Name

**Password**  
Password

Remember Me

Login

## MEMBERS

User: farras Interest: keyword,...

WG: [All] Membership: [All] Country: [All] SEARCH

[ Cancel search ]

**Results for : farras**

Member Data	Project Data	Scientific Info	Contact
 Farràs, Rosa Centro de Investigación Príncipe Felipe (Spain) Centro de Investigación Príncipe Felipe cipf.es	WG1, WG2, WG3, WG4 M.Committee, Core Group Vice-Chair		

# ProteoCure Cost Action Network Opportunities for Funding and Collaboration

October 30, 2023 10:00 – 12:30 hours

## AGENDA

10.00 h (5')	Welcome	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure Olivier COUX, Chair, ProteoCure Cris RAJO, Grant Holder Manager, ProteoCure
10.05 – 10.50h (45')	<b>Funding Opportunities for Health Research under Horizon Europe</b>	<b>Marina MARTINEZ, Horizon Europe Programme Officer, CDTI SOST-Brussels, Directorate of European Programmes and Regional Cooperation</b>
10.50 – 11.30 h (40')	Success experiences from participation in EU-projects	Rune MATTHIESEN, WG2 Leader, ProteoCure. Coordinator of EVCA, European Call Twinning 2020 Rosa BARRIO, Grant Awarding Coordinator, ProteoCure. Coordinator of COST Proteostasis and UPSTREAM, ITN program Manuel S. RODRIGUEZ, Science communication co-leader, ProteoCure, Coordinator of ubiCODE, Marie Skłodowska-Curie Actions Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project, HORIZON.2.1 - Health Olivier COUX, Chair, ProteoCure
11.30 – 12.20 h (50')	Get your Project Funded! - Working Group for ProteoCure funding proposals	All attendees
12.20 – 12.30 h (10')	Closing Remarks & Future Actions	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure COST Action Olivier COUX, Chair, ProteoCure COST Action





# HORIZON EUROPE

## THE EU RESEARCH & INNOVATION PROGRAMME

2021 – 2027

PhD MARINA MARTINEZ

Workshop **PROTEOCURE COST ACTION**  
Network Opportunities for Funding and  
Collaboration

30-October-2023



# **Funding opportunities in health under Horizon Europe...**

# Horizon Europe today: An evolution, not a revolution?



© European Union 2021

# Horizon Europe work programmes

What work programmes are, what they cover, download available Horizon Europe work programmes.

## PAGE CONTENTS

[Work programmes under Horizon Europe](#)

[View available work programmes](#)

## Work programmes under Horizon Europe

Work programmes set out funding opportunities under Horizon Europe.

One specific programme under Horizon Europe is implemented through the following:

The main work programme

- Marie Skłodowska-Curie actions and research infrastructures under Pillar I
- all clusters under Pillar II
- European innovation ecosystems under Pillar III
- the part widening participation and strengthening the European Research Area

Other work programmes cover

- European Research Council (ERC)
- Joint Research Centre (JRC)
- European Innovation Council (EIC)

A significant part of Pillar II of Horizon Europe will be implemented through institutionalised partnerships, particularly in the areas of Mobility, Energy, Digital and Bio-based economy, which will also have separate work programmes.

The activities of the [European Institute of Technology \(EIT\)](#) are set out in separate programming documents.


[https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes\\_en](https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes_en)





 **Horizon Europe Work programme (2023-24) - General introduction (draft)** [Download](#)   
English (1.49 MB - PDF)

 **Horizon Europe Work programme (2023-24) - EU Missions (draft)** [Download](#)   
English (2.2 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 1 (draft)** [Download](#)   
English (2.64 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 2 (draft)** [Download](#)   
English (1.86 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 4 (draft)** [Download](#)   
English (4.8 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 5 (draft)** [Download](#)   
English (4.83 MB - PDF)


 **Horizon Europe Work programme (2023-24) - Cluster 6 (draft)** [Download](#)   
English (6.25 MB - PDF)

 **Horizon Europe Work programme (2023-24) - European Innovation Ecosystems (draft)** [Download](#)   
English (963.81 KB - PDF)

 **Horizon Europe Work programme (2023-24) - MSCA (draft)** [Download](#)   
English (1.4 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Infrastructures (draft)** [Download](#)   
English (1.83 MB - PDF)

 **Horizon Europe Work programme (2023-24) - WIDERA (draft)** [Download](#)   
English (1.75 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Annexes (draft)** [Download](#)   
English (1 MB - PDF)

# All the Info and updates on the calls...

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

Funding & tender opportunities  
Single Electronic Data Interchange Area (SEDIA)

SEARCH FUNDING & TENDERS ▾ HOW TO PARTICIPATE ▾ PROJECTS & RESULTS WORK AS AN EXPERT SUPPORT ▾

Find calls for proposals and tenders

Search calls for proposals and tenders by keywords, programmes... Search

### EU Programmes


Asylum, Migration and Integration Fund (AMIF)	Border Management and Visa Instrument (BMVI)	Citizens, Equality, Rights and Values Programme (CERV)	Connecting Europe Facility (CEF)	Creative Europe Programme (CREA)	Customs Control Equipment Instrument (CCEI)
Customs Programme (CUST)	Digital Europe Programme (DIGITAL)	Erasmus+ Programme (ERASMUS)	European Regional Development Programme	EU External Action (RELEX)	EU4Health Programme (EU4H)
Euratom Research and Training Programme (EURATOM)	Europe Direct (ED)	European Defence Fund	European Maritime, Fisheries and Aquaculture Fund (EMFAF)	European Parliament (EP)	European Social Fund + (ESF)
European Solidarity Corps (ESC)	Fiscalis Programme (FISC)	<b>Horizon Europe (HORIZON)</b>	Information Measures for the EU Cohesion policy (IMREG)	Innovation Fund (INNOVFUND)	Internal Security Fund (ISF)

*ProteoCure Cost Action Network Opportunities for Funding and Collaboration*  
*October 30, 2023 10:00 – 12:30 hours*





# Main type of collaborative projects in the clusters of Pilar-II



**ATTENTION:** In all these schemes, and for all sort of partners in your consortium, you will get **25% additional INDIRECT COSTS**

## Types of actions... **The most usual ones!**

- ❑ **Research and innovation action (RIA)** → Activities aiming primarily to establish new knowledge and/or to explore the feasibility of a new or improved technology, product, process, service or solution. This **may include basic and applied research, technology development and integration, testing, demonstration and validation on a small-scale prototype in a laboratory or simulated environment.**
- ❑ **Innovation action (IA)** → Activities directly aimed at producing plans and arrangements or designs for new, altered or **improved products, processes or services**, possibly **including prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.**
- ❑ **Coordination and support action (CSA)** → Activities contributing to the objectives of the Horizon Europe programme, excluding research and innovation activities.

## Who can participate in these collaborative projects?

**ANY organisation (PUBLIC or PRIVATE)** can participate as a partner or coordinator, receiving **upto** 100% funding → **Minimum conditions:**

**ATTENTION: For RIAs & IAs, MINIMUM in the CONSORTIUM are 3 partners from 3 MMSS or Associated Countries (out of them, AT LEAST 1 comes from a MMSS)**

■ **EU Member States (27) →**  
Attention with some Hungarian Universities!

■ **Associated Countries (16+1)**

Albania  
Armenia  
Bosnia & Herzegovina  
Faroe Islands Georgia  
Iceland  
Israel  
The former Yugoslav Republic of Macedonia\* Republic of Moldova  
Montenegro  
**Norway**  
Serbia  
Tunisia  
Turkey  
Ukraine  
Morocco.... **YES UK & Canada**



Please, check the updated list of associated countries and the status of the association agreements with the EU → [PDF](#)



# It's official: UK to associate to Horizon Europe

07 Sep 2023 | News

*After multiple false dawns, London and Brussels have finally agreed a deal to allow the UK to rejoin. The UK will also join the Copernicus space programme, but is out of Euratom and the ITER fusion project*

By David Matthews



European Commission President Ursula von der Leyen with UK Prime Minister Rishi Sunak. Photo: Simon Walker / No 10 Downing Street



## In more detail

As of 1 January 2024, researchers and organisations in the UK will be able to participate in **Horizon Europe** on par with their counterparts in EU Member States and will have access to Horizon Europe funding. This will reinforce the opportunity to be part of a worldwide network of researchers and innovators aimed at tackling global challenges in climate, energy, mobility, digital, industry and space, health, and more.

Association to **Copernicus** will enable the UK's contribution to a strategically important space programme with a state-of-the-art capacity to monitor the Earth and to access its services. Copernicus makes an essential contribution in reaching our European Green Deal and net-zero objectives.

The UK will also have access to services from the EU Space Surveillance and Tracking, a component of the EU Space Programme.

Check this [link](#) for details!

Up to now, they have been forced to rely on UK equivalent grants and funding instead of being seamlessly integrated into Horizon Europe.

While UK academics have still been able to join consortia under the industrially-focused Pillar 2 of the programme - the biggest part by value - uncertainty about the future meant that UK participation in the programme *halved*, raising fears that UK scientists were being forced out of European academic networks built up over decades.

UK-based ERC grant winners have faced an *agonising choice* over whether to move to the EU to keep their awards, or stay and settle for a UK equivalent scheme.

## SOME Hungarian universities (NOT ALL) in your consortia...



Establishment of a "substitute fund" for certain HU universities involved in Horizon Europe projects

Due to the Council Implementing Decision (EU) 2022/2506 of 15 December 2022, **a group of (so not all) Hungarian universities** operating as public interest trusts (“model changing universities”) **can participate but cannot get funding** from Horizon Europe projects.

In order to maintain the R&I collaborations, a “**substitute fund**” of 5 billion HUF has been established via our funding agency, the National Research and Innovation Office.

**With the help of these grants, the universities concerned can cover the costs related to their participation in Horizon Europe** (and other centrally managed EU programmes).

The details are available in English on the following website →

<https://nkfih.gov.hu/english/news-of-the-office/correct-interpretation>

# Remember the structure of the workprogrammes...




Table at the beginning of each topic

## RECOMMENDATION:

Do not go directly to the topic but you must read the introductions (WP/Destination)!



**Let's check some opportunities for participating in the coming months...**

# Cluster-1 Health...

**\*We will check only those topics that are going to open in the coming weeks**

<https://cluster-health-horizon-europe-brokerage2024.b2match.io/>



2 June 2023

## CLUSTER Health - Horizon Europe Brokerage Event 2024

Home Timetable & How it works? Oral presentations/ Pitching session FAQ Contact

### Don't miss the opportunity to get involved in the next Horizon Europe 2024 Health proposals!

Friday, 2nd June 2023 | 09:30 - 18:30 CET

The 2024 calls are already open for submission; this will be the second round of calls of the CL1 Work Programme 2023-2024.

The European action **HNN3.0** together with the European Commission, Enterprise Europe Network and NCP WideraNet is organizing the next **Horizon Europe Brokerage Event on the 2024 Cluster 1 Health calls for proposals.**

The Brokerage Event is organized consecutively to the **Cluster 1 Health INFODAY** that will take place on June 1st.

This international partnering event will help you to build your consortium for the upcoming 2024 calls of the 2023-2024 Health Work Programme.

**IMPORTANT TO READ!!!**

The event is free of charge but registration and profile activation are mandatory to attend the brokerage event.

**Register now**  
Open until 29 May 2023

ORGANISED BY





<https://horizon-europe-health-ssh-brokerage.b2match.io/>



## Horizon Europe Health & SSH Brokerage Event

Build your consortium !

5 June 2023 9:00 - 17:00 ON SITE

HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 10105729

5 June 2023  
Paris, France

Horizon Europe Health & SSH Brokerage event

[Home](#) [Timetable & How it works?](#) [Oral presentations/ Pitching session](#) [FAQ](#) [Contact](#) [Travel and accomodation](#)

## Don't miss the opportunity to get involved in the next Horizon Europe 2024 Health proposals!

Monday, 5th June 2023 | 09:30 - 17:00 CET

The European action **HNN3.0** is organizing the next Brokerage Event dedicated to Horizon Europe **HEALTH** calls for proposals 2024 where the involvement of partners with specific expertise in **SOCIAL SCIENCES AND HUMANITIES (SSH)** is of major importance.

Several topics from the Health Cluster Work Programme require the **effective contribution of SSH disciplines** and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. A topic from Cluster 2 also requires expertise from the Health sector.

### REGISTRATION

Closed since 30 April 2023

LOCATION Campus Condorcet - Aubervilliers site - 8 Cr des Humanités, 93300 Aubervilliers

### ORGANISED BY



# EUROPEAN REGIONS RESEARCH & INNOVATION NETWORK

Your Brussels-based network supporting regional and local stakeholders to develop and enhance research and innovation capacities.

[Find out more](#)

<https://errin.eu/>



By Agnieszka Wieczorek Jetha 29/06/2023

## ERRIN Spring AGM 2023 – taking stock of the EU Missions

ERRIN's Spring Annual General Meeting (AGM) 2023 took place on 22 June this year. As always, it brought together the large and dynamic community of member regions and cities. Following the format part with the update from the network, the main focus was the EU Missions, approached in two policy debates, on the support and implementation frameworks in Adaptation, Ocean and Waters and Soil Missions, and the governance innovation and the perspective on Cities and the Cancer Missions.



By Agnieszka Wieczorek Jetha 22/06/2023

## Plenary Meeting of the S3 European Hydrogen Valleys Partnership and call for input

On 20 June 2023, ERRIN participated in the Plenary Meeting of the S3 European Hydrogen Valleys Partnership, hosted in the House of the Dutch Provinces in Brussels. In this context, ERRIN with its Energy & Climate Working Group is in the process of producing an input paper building on the work of the S3 Partnership on Hydrogen Valleys and collecting ERRIN's members' needs, challenges and solutions.



By Heidi Johansson 14/06/2023

## ERRIN at the Second Forum of the Mission on Adaptation to Climate Change

This week, ERRIN participated in the Second Forum of the Mission on Adaptation to Climate Change, organised in our member region Blekinge, Sweden. As a Friend of the Mission, ERRIN joined the pre-conference workshop to present how the network is supporting regions and their R&I ecosystems in developing EU projects, while also promoting the Pathways2Resilience call for Expressions of Interest.





# EUROPEAN REGIONS RESEARCH & INNOVATION NETWORK

Your Brussels-based network supporting regional and local stakeholders to develop their innovation ecosystem and enhance research and innovation capacities.

[Find out more](#)

<https://errin.eu/>





# HEALTH

ERRIN's Health Working Group (WG) supports members with early intelligence and regular updates about EU-level health policy-related issues, regulations, EU programmes and their funding opportunities. Creating opportunities for interregional cooperation in the Health area is one of the WG's main objectives. The WG is also a vehicle for networking, profile raising and promotion of good practices and projects among health stakeholders in the ERRIN regions.

Representatives of Brussels-based offices leading the work of Health Working Group.



**Helga Aunemo**  
Stavanger Region European Office




**Maria Tørnø Østergaard**  
Greater Copenhagen EU Office



**Ylva Reinsert**  
Region Skåne



**Beatriz Irala Aliaga**  
Government of Navarra



**Cédric Dumas**  
Ile-de-France Europe


## Future Related ERRIN Working Group Meetings



**POLICY WG MEETING: LOOKING AHEAD: HORIZON 2025-2027, EU MISSIONS & FP10**  
Ewa Chomicz Thu, 19/10/2023 - 10:30

The next ERRIN Policy Working Group meeting will focus on Horizon Europe strategic planning for 2025-2027, taking stock of EU Missions and preparations to FP10. The event will take place on Thursday

[SIGN UP](#)



21/11/2023 - 10:00  
**Event Horizon4Poland'23 "PARTNERSHIP IS THE NEW LEADERSHIP"**  
The Industry Contact Points within the Łukasiewicz Research Network invite you to the largest matchmaking event – Horizon4Poland'23, which will take place on 21-22 November 2023 in Norblin Factory in Warsaw.



16/11/2023 - 14:00  
**ERRIN Extraordinary General Meeting**  
The ERRIN Extraordinary General Meeting will take place on 16 November 2023 from 14:00-16:00 CET in the ERRIN premises. This Meeting is organised to make the necessary changes to the ERRIN Articles of Association following requirements by the new code for Belgian companies and associations. A minimum of 2/3 of the ERRIN members must be represented at the Meeting, and therefore engagement of each member is of crucial importance.



16/11/2023 - 09:00  
**Research & Innovation Transforming European Healthcare**  
The Slovenian Business & Research Association (SBRA), in cooperation with Istanbul IT Valley, the Lithuanian RDI Liaison Office in Brussels (LINO), the NCBR Office in Brussels, Eötvös Loránd University and the National Research, Development, and Innovation Office in Hungary have the pleasure to invite you to Research & Innovation Transforming European Healthcare taking place in Brussels, Belgium.



27/10/2023 - 09:30  
**Polish-Italian cooperation in the field of biomedicine**  
The Polish Academy of Sciences (PAN) and the Research Council of Italy (CNR) are organising a conference on Polish-Italian cooperation in the field of biomedicine, on 27 October in Rome. The meeting will be an occasion to meet researchers from Poland and Italy, discuss relevant scientific questions, and explore opportunities for future collaborative research.



24/10/2023 - 13:30  
**Immune systems in flames - what could EU research do?**  
Welcome to a roundtable event on "Inflammation in Health and Disease" organised by InFlames Flagship and MEP Ville Niinistö. The workshop provides an opportunity to discuss between representatives of the European Institutions, researchers and stakeholders on inflammation and the lack of EU's contributions to inflammation research, innovation and policies.



20/10/2023 - 10:00  
**ERRIN Intro Coffee**  
The ERRIN Secretariat is pleased to invite you to the upcoming ERRIN Intro Coffee, aiming to offer a concise introduction to ERRIN and its services, as well as encourage networking between members. The meeting is directed mainly towards new network members and colleagues, but all interested members are welcome to participate. Join us in person at ERRIN on 20 October!



## A NETWORK OF KNOWLEDGE AT THE SERVICE OF EUROPE

### ABOUT IGLO

IGLO is an informal association of Brussels-based non-profit R&D Liaison Offices. The aim of IGLO is to facilitate and enhance the interaction, information exchange and co-operation between Members of IGLO, their national research systems and the European institutions on issues related to EU RTD, in particular, the Framework Programme.

### Health

The goal of Health WG is to build a platform for discussion on the most important EU activities and R&I developments in the field of health, in order to strengthen collaboration and information sharing within the IGLO network. This WG is mapping the key institutions and stakeholders in the field of health, sharing knowledge, ideas and most effective instruments of the programmes related to health R&I. The WG meets as required.

**Contact:**

Co-Chair Joep Roet, Neth-ER (roet @ neth-er.eu)

Co-Chair Jens Jäger, Helmholtz Association (jens.jaeger @ helmholtz.de)

Co-Chair Inga Benner, KoWi (inga.benner @ kowi.de)

# Specific Impact for Health Cluster...

## Specific Impacts of Cluster-1:

[...] Research and innovation actions under this cluster will be key to address the health-related challenges by advancing knowledge and capabilities, **improving our understanding of health and diseases, developing innovative methodological and technological solutions to better manage health and diseases**, and designing sustainable approaches for the digital transformation and delivery of integrated, **person-centred** and equitable health and care services with improved accessibility and health outcomes supported by needs-driven innovation and reliable supply chains in Europe. [...]





# Structure of Cluster-1

- **Destination 1** – Staying healthy in a rapidly changing society
- **Destination 2** – Living and working in a health-promoting environment
- ➔ **Destination 3** – Tackling diseases and reducing disease burden
- **Destination 4** – Ensuring access to innovative, sustainable and high-quality health care
- ➔ **Destination 5** – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
- **Destination 6** – Maintaining an innovative, sustainable and globally competitive health-related industry

**\*Only topics from call-2024 still opened!!!**



EU partnership on personalised medicine

#ICPerMed  
INTERNATIONAL CONSORTIUM



# Publication of the Strategic Research and Innovation Agenda for Personalised Medicine

28 April 2023 ICPeMed is happy to announce the publication of the Strategic Research and Innovation Agenda (SRIA) for Personalised Medicine (PM). This SRIA will support a wide range of stakeholders and experts to further develop programs, activities, and research towards PM and care, as well as prevention. In line with this mission, its main intention is to support the planned new European Partnership for Personalised Medicine (EP PerMed).

The SRIA aims to ensure that the long-term vision of EP PerMed is translated into tailored roadmaps with funding and supporting activities, objectives and measurable outcomes. Therewith, the SRIA complements the EP PerMed proposal that has recently been submitted to the European Commission (EC).

The SRIA was developed by a dedicated drafting group, composed of Member States' representatives and in close collaboration with the EC. The drafting group was established in 2021 in order to support the first phase of the EP PerMed preparations, i.e. the development of a draft proposal for EP PerMed, that was published by the EC in February 2022, and the SRIA for PM.

The structure and content of the SRIA is based on the drafting group members' knowledge, existing strategic documents, and further available information. Even more importantly, it presents the outcome of several activities and events of which some were organised with the support of the EC, the International Consortium for Personalised Medicine (ICPerMed), and connected consortia like the European Research Area Network for Personalised Medicine (ERA PerMed).



<https://www.icpermed.eu/>



## ICPerMed Workshop 11 | 2023 Siena

The 5<sup>th</sup> ICPerMed Workshop will focus and explore the latest developments in technology and innovation that are driving the field of personalised medicine. The workshop aims to showcase experiences of researchers, clinicians, biotech and industry leaders, to provide insights on how to drive personalised medicine related innovations in the healthcare sector, and to present selected and promising technologies/tools. This ICPerMed event will also promote good practices.

**Date:** 14-15 November, 2023 (1 ½ day event)



Opening: 30 Mar 2023

Deadline(s): 19 Sep 2023 (First Stage), 11 Apr 2024 (Second Stage)

**CSA for preparation of the future co-funded partnership on Pandemic Preparedness**

Opening: 26 Oct 2023

Deadline(s): 11 Apr 2024

Opening: 25 Apr 2024

Deadline(s): 25 Sep 2024

**Destination 3. Tackling diseases and reducing disease burden ..... 59**

**Call - Tackling diseases (Two stage - 2024)..... 91**

Conditions for the Call ..... 92

HORIZON-HLTH-2024-DISEASE-03-08-two-stage: Comparative effectiveness research for healthcare interventions in areas of high public health need ..... 93

HORIZON-HLTH-2024-DISEASE-03-11-two-stage: Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness ..... 96

HORIZON-HLTH-2024-DISEASE-03-13-two-stage: Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders ..... 99

HORIZON-HLTH-2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions ..... 102

**Call - Tackling diseases (Single stage - 2024)..... 105**

Conditions for the Call ..... 105

HORIZON-HLTH-2024-DISEASE-08-12: Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness ..... 106

HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential..... 108

**Call - Partnerships in Health (2024)..... 111**

Conditions for the Call ..... 111

HORIZON-HLTH-2024-DISEASE-09-01: European Partnership: One Health Anti-Microbial Resistance ..... 112



<b>Specific conditions</b>	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of between EUR 7.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 50.00 million.
<i>Type of Action</i>	Research and Innovation Actions
<i>Eligibility conditions</i>	<p>The conditions are described in General Annex B. The following exceptions apply:</p> <p>In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.</p> <p>The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.</p>
<i>Award criteria</i>	<p>The criteria are described in General Annex D. The following exceptions apply:</p> <p>The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.</p>

## HEALTH UNION: Identifying top 3 priority health threats

HERA, together with the Member States, identifies on an annual basis three specific high impact health threats to ensure preparedness and response, in particular by addressing possible gaps in the availability and accessibility of medical countermeasures (MCMs).

### Top 3 serious cross-border threats:

#### 1 Pathogens with high pandemic potential, notably due to:

- rapid transmission mode;
- likelihood to reach a sensitive population, for example persons with minimal pre-existing immunity;
- their high potential to cause high morbidity and mortality

This largely includes respiratory RNA viral families.



**Scope:** As shown by the COVID-19 pandemic, infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is expected to accelerate due to among other factors, climate change, and thus a proactive approach to the development of vaccines and inhibitors for the cellular uptake of viruses in preparedness for future infectious disease outbreaks is needed. The availability of vaccines and candidates that inhibit cellular uptake of viruses would provide a critical preparedness measure against future health threats, in particular against pathogens with high pandemic potential meeting the criteria identified by the Health Emergency Preparedness and Response Authority (HERA)<sup>182</sup>.

Proposals should follow innovative approaches to characterise host-pathogen interactions with a view to inhibit viral replication, viral proteases, viral exit strategies and to develop therapeutic antibodies and vaccines that target viruses with high epidemic or pandemic potential for the EU. Proposals should focus on the following viruses: Hendra and Nipah virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus. Proposal should take into account sex and gender aspects.

#### 2 Chemical, biological, radiological and nuclear (CBRN) threats originating from accidental or deliberate release.

**For chemical threats, substances identified based on:**

- likelihood to occur;
- potential impact on human health, resulting in death, temporary incapacitation or permanent harm, regardless of their origin or their method of production.

**Radiological and nuclear threats identified based on**

- likelihood of their occurrence in various scenarios, e.g. resulting from an incident/accident, or their use in a deliberate release.

**Biological threats, with pandemic potential identified on the basis of**

- especially the threat potential due to a deliberate or accidental release.

#### 3 Antimicrobial resistance, which pose one of the greatest risk to human health, with antibacterial resistance alone causing an annual estimate of 1.27 million deaths globally.







**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “*Tackling diseases and reducing disease burden*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities have an increased knowledge on viruses with epidemic potential and in particular a better understanding of pathogen–host interactions for the targeted development of vaccines and inhibitors for the prevention of viral infection and the viral transmission during pathogenesis.
- The scientific and clinical communities have access to novel approaches for the prevention and treatment for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
- The scientific and clinical communities have access to experimental vaccine candidates and candidates that inhibit cellular uptake of viruses against emerging or re-emerging viral infections for further clinical investigation.

A diverse and robust development pipeline of vaccine candidates and candidates that inhibit cellular uptake of viruses is available to fight emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.



Proposals should address several of the following areas:

- Identification and characterisation of receptors on the host cell that enable the docking and internalisation of a virus with a particular emphasis on the diversity of cellular entry receptors and tissue specificity.
- Identification and characterisation of viral surface proteins that are capable of interacting with host target cells.
- Characterisation of the mechanism of viral uptake in the host cell with regard to the topology and the dynamics of the host receptor – virus ligand interaction.
- Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention.

Proposals could consider the inclusion of the European Commission's Joint Research Centre (JRC) research infrastructure (Nanobiotechnology laboratory) for biophysical characterisation of recombinant proteins, antigens and therapeutic antibodies, and its expertise at the interface between the research activities and regulatory aspects. In that respect, the JRC will consider collaborating with any successful proposal and this collaboration, when relevant, should be established after the proposal's approval.



# Imagining the future of pandemics and epidemics

A 2022 perspective



## 2.4 Technology and innovation



Key message:

**Tap into the potential of emerging technologies to improve future pandemic and epidemic preparedness.**

Practical ways forward:

- Capitalize on current investments in global pathogen genomic surveillance infrastructure and in biotech innovations.
- Explore new therapeutics approaches for example, antivirals to prevent severe disease and death.
- Leverage advancements in nanobiotechnology and genome editing for future pan-viral prevention.
- Improve sharing of benefits stemming from health care innovation and research and development (R&D) across nations and regions.
- Strengthen biosafety measures globally and highlight that biosecurity equals bioprospersity.
- Leverage the benefits of biobanks and biodepositories to increase preventive capacity and improve the ability to investigate novel pathogens.



Key message:

**Maximize investment in training and future skills to improve pandemic and epidemic preparedness.**

Practical ways forward:

- Exercise public health and social measures for seasonal influenza epidemics and other respiratory pathogen outbreaks to inform capacity building and personnel training.
- Consider simulation exercises on a city level to identify gaps in training, skills and operations.
- Consider multilateral, multidisciplinary exercises and training programmes to build future skill agendas.
- Develop a global funding mechanism for health care and pandemic R&D to support research for global goods and increase research capacity in all countries.



**“Collaborative public-private partnerships are a critical tool to push the world towards the best-case scenario.”**

Ms Allison Neale, Vice President of Public Policy  
Henry Schein, Inc.  
Managing Director  
Henry Schein Cares Foundation

**Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society ..... 145**

**Call - Tools and technologies for a healthy society (Two stage - 2024) ..... 165**

Conditions for the Call ..... 166

HORIZON-HLTH-2024-TOOL-05-06-two-stage: Innovative non-animal human-based tools and strategies for biomedical research ..... 167

**Call - Tools and technologies for a healthy society (Single stage - 2024) ..... 169**  
Conditions for the Call ..... 170  
HORIZON-HLTH-2024-TOOL-11-02: Bio-printing of living cells for regenerative medicine ..... 171



Opening: 26 Oct 2023

Deadline(s): 11 Apr 2024






**HORIZON-HLTH-2024-TOOL-11-02: Bio-printing of living cells for regenerative medicine**

Opening: 26 Oct 2023


Deadline(s): 11 Apr 2024

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of between EUR 6.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 25.00 million.
<i>Type of Action</i>	Research and Innovation Actions
<i>Eligibility conditions</i>	The conditions are described in General Annex B. The following exceptions apply:  In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
<i>Award criteria</i>	The criteria are described in General Annex D. The following exceptions apply:  The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.



**Expected Outcome:** This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to several of the following expected Outcomes:


- Biomedical scientists will access entire bio-printing units for regenerating human tissue.
- Availability of larger-scale bio-printed tissues for biomedical research purposes to both industry and academia.
- Healthcare professionals acquire information on the safe and effective use of advanced therapies.
- Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.
- Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.



**Scope:** Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". 3D-printing in general is considered an advanced manufacturing technique and 3D-printing of non-viable biomaterials to serve e.g. as scaffold for cell growth or as structure for medical devices is already broadly used.

However, bio-printing technology involving living cells is still in early stages of development, but has a huge potential for tissue engineering, drug testing and other biomedical applications. Tissue-specific functional 3D bio-printing is a new approach for transplantation applications in regenerative medicine, relying on the fabrication of tissues and organs with respect to the desired shape and function and their delivery and application in vivo. "In-situ bio-printing" known as printing cells and biomaterials directly onto or in a patient, or 4D bio-printing, which introduces a "time" variable that allows 3D printed materials to change shape or function when external stimulus is applied, are recent developments facing multiple additional challenges.

Despite some success of 3D bio-printing with thin tissue, thick tissue and complex organs remain a bottleneck because it is difficult to sufficiently mimic their metabolic needs, and the scientific knowledge about their intimate architecture and interplay with other tissues are not sufficiently elucidated. Next to these limitations are a lack of standardised manufacturing protocols and standardised bio-ink formulations with tuneable properties, unstable cellular behaviour, material biocompatibility and printability, etc. Taken together, 3D bio-printing is confronted with several challenges that currently hamper its large-scale deployment.



To overcome these challenges, researchers should work in multidisciplinary teams with engineers, biomedical scientists, cell biologists and medical doctors and proposals should address most of the following activities:

- Design the best bio-printing strategy for at least one type of tissue thanks to a better understanding of the interconnections of the different cell types inside the chosen tissue or organ
- Develop or improve existing equipment able to print bio-constructs with higher resolution in a shorter time using various biomaterials and different cell types
- Cover all steps of the bio-printing suite, including cell collection, cell differentiation and expansion, imaging, modelling, bio-ink formulation, actual bio-printing, nutrient supply, process monitoring and cell-construct delivery at target site
- Scale-up the chosen bio-printing technology to a GMP-conform manufacturing process
- Combine different bio-printing technologies in order to obtain fully functional synthetic constructs of complex tissues or organs.

✓ **The chosen medical area (tissue, organ, condition) should be duly justified.** Sex differences at the cellular level should be taken into consideration.

✓ **Preclinical stage and early clinical development are eligible.** The involvement of SMEs is encouraged.



**Cluster – 4**  
**“Digital, Industry and Space”**



<https://research-innovation-community.ec.europa.eu/events/1z2tF6FuhrcaQJ8b4G6pVu/overview>

## The research and innovation community platform

Connecting researchers across borders and disciplines. Take part in events, access exclusive content, widen your network.

Home **Events** Community How it works

COMING SOON

### Horizon Europe info days - Cluster 4

This event aims to inform potential applicants about the funding opportunities of the 2024 calls of Horizon Europe Cluster 4 Work Programme 2023-2024

11 October 2023 - 12 October 2023  
09:30 (GMT+02:00)

807 members are attending this event

[Log in](#) [Register now](#)

Day 1 Day 2

09:30 **Welcome and agenda setting**

11 October 2023

09:30 - 10:00(GMT+02:00) CLUSTER 4 CHANNEL

[Add to favourites](#) [Show details](#)

10:00 **Destination 1 - Climate Neutral, Circular and Digitized Production**

11 October 2023

10:00 - 12:00(GMT+02:00) CLUSTER 4 CHANNEL

[Add to favourites](#) [Show details](#)

14:00 **Destination 2: Increased Autonomy in Key Strategic Value Chains for Resilient Industry**

11 October 2023

14:00 - 15:40(GMT+02:00) CLUSTER 4 CHANNEL

[Add to favourites](#) [Show details](#)

16:00 **Cross-cutting session**

11 October 2023

16:00 - 17:00(GMT+02:00) CLUSTER 4 CHANNEL

[Add to favourites](#) [Show details](#)

[https://assets.ctfassets.net/cdx728z92xkc/2YZzNLk2alw5Y31HgpcEzz/00476ef8af60412d13c3f3d1707301d3/ec\\_rtd\\_cluster-4-infoday-agenda.pdf](https://assets.ctfassets.net/cdx728z92xkc/2YZzNLk2alw5Y31HgpcEzz/00476ef8af60412d13c3f3d1707301d3/ec_rtd_cluster-4-infoday-agenda.pdf)

## Specific Impact for Cluster-4...

### Specific Impacts of Cluster-4:

[...] Progress in **digital and industrial technologies**, including in space, shape all sectors of the economy and society. They **transform the way industry develops, produces new products and services**, and are central to any sustainable future. The COVID-19 crisis of 2020 has shown the necessity to strengthen Europe's **industrial base, enhancing its resilience and flexibility** both in terms of technologies and supply chains to **reduce EU dependencies on third countries**. It has also created a new urgency around addressing key societal challenges like **sustainability or inclusiveness**. In a globalised world of heightened uncertainties and volatile geopolitical interests, what is at stake is not only Europe's prosperity and economic competitiveness, but also its ability to autonomously source and provide crucial **raw materials, technologies and services** that are safe and secure for industry as a whole. [...]



## Estructura del Cluster-4

- **Destination 1:** Climate neutral, circular and digitised production
- **Destination 2:** A digitised, resource-efficient & resilient industry
- **Destination 3:** World leading data and computing technologies
- **Destination 4:** Digital and emerging technologies for competitiveness and fit for the green deal
- **Destination 5:** Strategic autonomy in developing, deploying and using global space-based infrastructures, services, applications and data
- **Destination 6:** A human-centred and ethical development of digital and industrial technologies
- Other Actions not subject to calls for proposals






**Destination 2: Increased Autonomy in Key Strategic Value Chains for Resilient Industry**

<b>Destination 2: Increased Autonomy in Key Strategic Value Chains for Resilient Industry</b> .....	<b>93</b>
<b>Call - RESILIENT VALUE CHAINS 2024 TWO STAGE</b> .....	<b>147</b>
Conditions for the Call .....	148
Strategic innovation markets driven by advanced materials .....	149
HORIZON-CL4-2024-RESILIENCE-01-35: Biodegradable polymers for sustainable packaging materials (IA) .....	149
<b>HORIZON-CL4-2024-RESILIENCE-01-36: Advanced biomaterials for the Health Care (IA)</b> .....	<b>151</b>
Improving the resilience of EU businesses, especially SMEs and Startups.....	154
<b>Call - RESILIENT VALUE CHAINS 2024</b> .....	<b>154</b>
Conditions for the Call .....	154
Raw Materials for EU open strategic autonomy and successful transition to a climate-neutral and circular economy .....	155
HORIZON-CL4-2024-RESILIENCE-01-01: Exploration of critical raw materials in deep land deposits (RIA) .....	155
HORIZON-CL4-2024-RESILIENCE-01-04: Technologies for processing and refining of critical raw materials (IA) .....	158
HORIZON-CL4-2024-RESILIENCE-01-08: Rare Earth and magnets innovation hubs (IA) .....	160
HORIZON-CL4-2024-RESILIENCE-01-10: Addressing due diligence requirements in raw materials supply chains. (CSA).....	163
HORIZON-CL4-2024-RESILIENCE-01-11: Technologies for extraction and processing of critical raw materials (IA) .....	166
Safe and Sustainable by Design (SSbD) Chemicals and Materials .....	169
HORIZON-CL4-2024-RESILIENCE-01-24: Development of safe and sustainable by design alternatives (IA) .....	169
Improving the resilience of EU businesses, especially SMEs and Startups.....	172
HORIZON-CL4-2024-RESILIENCE-01-41: 'Innovate to transform' support for SME's sustainability transition (CSA) .....	172

Opening: 19 Sep 2023



Deadline(s): 07 Feb 2024 (First Stage), 24 Sep 2024 (Second Stage)





**HORIZON-CL4-2024-RESILIENCE-01-36: Advanced biomaterials for the Health Care (IA)**

<b>Specific conditions</b>	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of between EUR 6.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 31.00 million
<i>Type of Action</i>	Innovation Actions
<i>Technology Readiness Level</i>	Activities are expected to start at TRL 3-4 achieve TRL 5-6 by the end of the project – see General Annex B.
<i>Procedure</i>	The procedure is described in General Annex F. The following exceptions apply: This topic is part of the blind evaluation pilot under which first stage proposals will be evaluated blindly.
<i>Legal and financial set-up of the Grant Agreements</i>	The rules are described in General Annex G. The following exceptions apply: Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions.



Scope: Proposals should address at least four of the following activities:

- To enable a fast development of new advanced novel injectable biomaterials, digital tools such as modelling, simulation and characterisation techniques (including those provided by analytical infrastructures) assisted by advanced methods e.g. physics-based methods, machine learning or artificial intelligence.
- The innovation market of medical applications is fast growing and dependent on advanced biocompatible materials that can be printed or injected. The 4D materials will change their 3D structures after external impact such as thermic, electric, mechanical or radiation treatment.
- Proposals shall demonstrate new engineering strategies that present functional characteristics beyond bio-compatibility, and express properties that can be used to control the physiological environment (shape-memory, self-healing properties) and induce a response.
- Proposals shall address biomaterials with antibacterial properties contributing to the widespread bottleneck of antimicrobial resistance often encountered in clinical care
- Demonstrate the scaling of injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.
- The design for circularity has to develop, when relevant, bio-degradable or bio-absorbable biomaterials that are gradually eliminated by the body after fulfilling a purpose.

The biomaterials used should be safe and sustainable by design (SSbD), taking also into account any specific medical requirements.




Expected Outcome: This topic refers to the innovation market for *Healthcare and Medicine*, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.



**Scope:** Proposals should address at least four of the following activities:

- To enable a fast development of new advanced novel injectable biomaterials, digital tools such as modelling, simulation and characterisation techniques (including those provided by analytical infrastructures) assisted by advanced methods e.g. physics-based methods, machine learning or artificial intelligence.
- The innovation market of medical applications is fast growing and dependent on advanced biocompatible materials that can be printed or injected. The 4D materials will change their 3D structures after external impact such as thermic, electric, mechanical or radiation treatment.
- Proposals shall demonstrate new engineering strategies that present functional characteristics beyond bio-compatibility, and express properties that can be used to control the physiological environment (shape-memory, self-healing properties) and induce a response.
- Proposals shall address biomaterials with antibacterial properties contributing to the widespread bottleneck of antimicrobial resistance often encountered in clinical care
- Demonstrate the scaling of injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.
- The design for circularity has to develop, when relevant, bio-degradable or bio-absorbable biomaterials that are gradually eliminated by the body after fulfilling a purpose.

The biomaterials used should be safe and sustainable by design (SSbD), taking also into account any specific medical requirements.



**Few words on the partnerships...**



# Re-configuration of the EU Partnerships

New generation of objective-driven and more ambitious partnerships in support of agreed EU policy objectives

## Key features

- **Simple architecture and toolbox**
- **Coherent life-cycle approach**
- **Strategic orientation**

### Co-programmed

Based on Memoranda of Understanding / contractual arrangements; implemented independently by the partners and by Horizon Europe

### Co-funded

Based on a joint programme agreed by partners; commitment of partners for financial and in-kind contributions & financial contribution by Horizon Europe

### Institutionalised

Based on long-term dimension and need for high integration; partnerships based on Articles 185 / 187 of TFEU and the EIT-Regulation supported by Horizon Europe

**Main differences in the implementation and sources of funding**

# Overview of 49 candidate European Partnerships

## PILLAR II - Global challenges and European industrial competitiveness

CLUSTER 1: Health	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bioeconomy, Agriculture, ...
Innovative Health Initiative	Key Digital Technologies	Clean Hydrogen	Circular Bio-based Europe
Global Health Partnership	Smart Networks & Services	Clean Aviation	Rescuing Biodiversity to Safeguard Life on Earth
Transformation of health systems	High Performance Computing	Single European Sky ATM Research 3	Climate Neutral, Sustainable & Productive Blue Economy
Chemicals risk assessment	European Metrology (Art. 185)	Europe's Rail	Water4All
ERA for Health	AI-Data-Robotics	Connected and Automated Mobility (CCAM)	Animal Health & Welfare*
Rare diseases*	Photonics	Batteries	Accelerating Farming Systems Transitions*
One-Health Anti Microbial Resistance*	Made in Europe	Zero-emission waterborne transport	Agriculture of Data*
Personalised Medicine*	Clean steel – low-carbon steelmaking	Zero-emission road transport	Safe & Sustainable Food System*
Pandemic Preparedness* <i>Co-funded or co-programmed</i>	Processes4Planet	Built4People	
	Global competitive space systems**	Clean Energy Transition	
		Driving Urban Transitions	

- Institutionalised Partnerships (Art 185/7)
- Institutionalised partnerships / EIT KICs
- Co-Programmed
- Co-Funded

\* *Calls with opening dates in 2023-24*

\*\* *Calls with opening dates not before 2022*

## PILLAR III - Innovative EU

### EIT

InnoEnergy

Climate

Digital

Food

Health

Raw Materials

Manufacturing

Urban Mobility

Cultural and Creative Industries

SUPPORT TO INNOVATION ECOSYSTEMS

Innovative SMEs

## CROSS-PILLARS II AND III

EU Open Science Cloud

# European Partnerships in Horizon Europe

Types of partnerships, how partnerships are being identified, candidates for partnerships, contact details, impact assessments.

## PAGE CONTENTS

**Types of partnership**

Identifying partnerships

Partnership candidates and contact details

## Types of partnership

The aim of European partnerships with EU and associated countries, the private sector, foundations and other stakeholders is to deliver on global challenges and modernise industry.

The Horizon Europe proposal lays down the conditions and principles for establishing European Partnerships. There are 3 types.

### Co-programmed European Partnerships

These are partnerships between the Commission and private and/or public partners. They are based on memoranda of understanding and/or contractual arrangements.

### Co-funded European Partnerships using a programme co-fund action

Partnerships involving EU countries, with research funders and other public authorities at the core of the consortium.

### Institutionalised European Partnerships

These are partnerships where the EU participates in research and innovation funding programmes that are undertaken by EU countries.

These partnerships require legislative proposals from the Commission and are based on a Council Regulation ([Article 187](#)) or a Decision by the European Parliament and Council ([Article 185](#)). They are implemented by dedicated structures created for that purpose.

Institutionalised partnerships will only be implemented where other parts of the Horizon Europe programme, including other types of partnership, would not achieve the desired objectives or expected impacts.

[EIT Knowledge and Innovation Communities](#) (KICs) are also institutionalised partnerships. EIT KICs aim to address skills shortages and are already established under Horizon 2020. Key partners in EIT KICs are higher education institutions, research organisations, companies and other stakeholders.

[https://ec.europa.eu/info/horizon-europe-next-research-and-innovation-framework-programme/european-partnerships-horizon-europe\\_en](https://ec.europa.eu/info/horizon-europe-next-research-and-innovation-framework-programme/european-partnerships-horizon-europe_en)

## Partnership candidates and contact details

The current list of candidate European Partnerships is found in Annex 7 of the [Orientations towards the first Strategic Plan for Horizon Europe](#).

Results from the structured consultation of EU countries are summarised in the report [European Partnerships under Horizon Europe: results of the structured consultation of Member States](#)

The partnership candidates are collected across 5 areas.

Full details of candidates, draft proposal documents and contact details below.

- [health](#)
- [digital, industry and space](#)
- [climate, energy and mobility](#)
- [food, bioeconomy, natural resources, agriculture and environment](#)
- [partnerships across themes](#)





## European Partnerships

European Partnerships are initiatives in which the EU Commission and private and/or public partners commit themselves to jointly support the development and implementation of a research and innovation program. They make a significant contribution to achieving the EU's political priorities, such as the Green Deal, Europe's digital strategy or pandemic preparedness.

[Read more](#)



# Los Lunes de CDTI-SOST Bruselas Primavera / Verano 2023

Sesión	Fecha	Contenido
1	24-Abril	Overview
2	08-Mayo	Cluster -1 Health (1 de 2)
3	22-Mayo	Cluster - 5 Energía
4	05-Junio	Cluster - 5 Transporte
5	12-Junio	Cluster – 6 Bioeconomía (1 de 3)
6	19-Junio	Cluster – 6 Agricultura & Food Production Systems
7	26-Junio	Cluster – 6 & 5 Medioambiente & Impacto Climático, Agua
8	03-Julio	Cluster -1 Health ( 2 de 2)
9	10-Julio	Cluster – 4 Industria
10	17-Julio	Cluster -4 ICT

GOBIERNO DE ESPAÑA  
MINISTERIO DE CIENCIA E INNOVACIÓN

CDTI  
SPAIN OFFICE FOR SCIENCE AND TECHNOLOGY  
INNOVACIÓN | SOST-BRUSSELS

2ª Temporada de Los Lunes de CDTI-SOST Bruselas (S2): Partenariados en el Clúster 1 de Horizonte Europa (Health)

Agenda Registro Agenda próximas sesiones Presentación Marta G. Quintanilla - Partenariados en el Clúster 1-Salud Grabación de la sesión

Mayo  
8  
Comienza: 11:00

Webinario online  
Evento terminado  
Añade al calendario

### Descripción:

La segunda temporada de los webinarios "Los Lunes de CDTI-SOST Bruselas" se centrará en ofrecer una visión actualizada sobre todos los partenariados relacionados con las diferentes temáticas y ámbitos de actuación del programa marco Horizonte Europa que están (o van a entrar) en funcionamiento en los próximos meses/años.

Los partenariados son una iniciativa de colaboración entre actores del sector público y privado en aspectos muy concretos de la investigación y la innovación. Este término, acuñado por la Comisión Barroso, engloba toda una serie de iniciativas que, a lo largo de los últimos 12 años, han evolucionado de forma paralela a los programas de trabajo de Programa Marco y han supuesto un impulso definitivo a la investigación e innovación en sectores y áreas muy específicos en Europa.

En esta 2ª sesión, Marta Gómez Quintanilla, representante en el comité de programa del Clúster -1 Salud en Horizonte Europa, nos dará una visión de los diferentes partenariados relacionados con este clúster. La sesión permitirá revisar las diferentes tipologías y objetivos detrás de cada una de estos partenariados, los actores, los criterios de puesta en marcha, así como una orientación a futuras iniciativas en discusión. Como siempre, ésta comenzará a partir de las 11:00 y contará con una duración de unos 60-90 minutos.



Inicio

GOBIERNO DE ESPAÑA  
MINISTERIO DE CIENCIA E INNOVACIÓN

CDTI INNOVACIÓN

SPAIN OFFICE FOR SCIENCE AND TECHNOLOGY

CDTI INNOVACIÓN SOST-BRUSSELS

2ª Temporada de Los Lunes de CDTI-SOST Bruselas (S8): Partenariados en el Clúster T de Horizonte Europa (salud)

Registro Agenda

Julio  
3  
Comienza: 11:00

Webinario online

El evento comenzará en:  
5D 3H 38M

Añade al calendario

### Descripción:

La segunda temporada de los webinarios "Los Lunes de CDTI-SOST Bruselas" se centrará en ofrecer una visión actualizada sobre todos los partenariados relacionados con las diferentes temáticas y ámbitos de actuación del programa marco Horizonte Europa que están (o van a entrar) en funcionamiento en los próximos meses/años.

Los partenariados son una iniciativa de colaboración entre actores del sector público y privado en aspectos muy concretos de la investigación y la innovación. Este término, acuñado por la Comisión Barroso, engloba toda una serie de iniciativas que, a lo largo de los últimos 12 años, han evolucionado de forma paralela a los programas de trabajo de Programa Marco y han supuesto un impulso definitivo a la investigación e innovación en sectores y áreas muy específicos en Europa.

En esta 8ª sesión de los webinarios "Los Lunes de CDTI-SOST" volvemos sobre los partenariados relacionados con Salud para centrarnos en la Iniciativa de Salud Innovadora (Innovative Health Initiative, IHI) de Horizonte Europa. IHI, heredera de la Iniciativa de Medicamentos Innovadores (Innovative Medicine Initiative, IMI) es un partenariado institucional perteneciente al Clúster de Salud del Pilar II. Sus principales impulsores son, por una parte, la Comisión Europea y por otra parte, las industrias del sector de la Salud representadas por COCIR, EFPIA/ Vaccines Europe, EuropaBio y MedTech Europe. Durante esta sesión se abordará la evolución de IMI a IHI, así como los objetivos y estructuras de la presente iniciativa. También se hará difusión de las próximas convocatorias, sobre cómo participar en ellas y cómo colaborar tanto en la evaluación de propuestas y seguimiento de los proyectos y sobre cómo influir en la conformación de nuevos tópicos para los próximos años.



## Commission proposals for new candidate European Partnerships are now public

Preparations of new European Partnerships that will be launched during the second half of Horizon Europe have reached an important milestone this week, when the European Commission presented [10 proposals for new candidate partnerships](#) to Member States and Associated Countries:

- Brain Health;
- Forests and Forestry for a Sustainable Future;
- Innovative Materials for EU (IM for EU);
- In-Orbit Demonstration and Validation;
- Raw Materials for the Green and Digital Transition;
- Resilient Cultural Heritage;
- Social Transformations and Resilience;
- Solar Photovoltaics;
- Textiles of the Future;
- Virtual Worlds.

This proposed portfolio will be discussed with Member States and Associated Countries in the coming months and may thus be subject to further changes.

The concept papers for the new candidates have been prepared by Commission services in line with the new impact-driven policy approach set out in Horizon Europe. This includes partnerships' contributions to delivering on European Commission priorities regarding the twin green and digital transitions, and to the Union's reinforced open strategic autonomy.

Member States and Associated countries have been engaged in the process early on, notably through the Partnership Knowledge Hub, which provides a dedicated forum for coordination and cooperation with Member States, Associated Countries, and related stakeholders involved in European Partnerships.

Another important input to the identification of new candidate partnerships was published last week by the [expert group](#) supporting strategic coordinating process for partnerships, who has prepared evidence-based advice for the development of the overall portfolio. Their report on "[Assessing European Partnerships against European policy priorities](#)" develops a methodology to better assess the relevance of European Partnerships as instruments to address the Union's political priorities.



# BRAIN HEALTH

General Information	
Proposed title of the European Partnership	<b>European Partnership on Brain Health</b>
Short description of the candidate partnership	Accelerating the delivery of preventive, diagnostic, therapeutic and care solutions to foster brain health <sup>1</sup> in citizens and patients, including through a better understanding of the functioning of the brain and by strengthening the alignment and synergies across European and global brain health research initiatives
Services directly involved	DGs RTD, SANTE, CNECT, GROW, JRC, EAC, EMPL, ENV
Context and problem definition	<p><b>Brain disorders are a leading cause of disability</b> in Europe and globally, putting a great burden on patients, families, caregivers and healthcare systems. <b>More research and innovation are needed</b> to develop effective disease-modifying treatments or cures, improved preventive measures, better diagnostics, but also evidence for policymakers, and this also implies a better understanding of the functioning of the brain.</p> <p>The total cost of brain disorders in Europe was estimated at €798 billion in 2010. Neurodegenerative diseases and dementia affect one third of the ageing population over 85 years. Mental disorders, including addictions, affect 12% of the entire population, while neurodevelopmental disorders affect 15% of children. The COVID-19 crisis, Russia's war of aggression against Ukraine, the energy crisis and inflation have further aggravated mental health, including for the most vulnerable.</p> <p>National efforts to address these challenges are insufficient, and enhanced coordination and collaboration among all stakeholders in Europe and globally are needed to tackle them collectively. Several initiatives have already been established in Europe aimed at achieving a concerted alignment and a strategic and financial defragmentation of research in brain health. These include the EU Joint Programme for Neurodegenerative Disease Research (<b>JPND</b>), the Network of European Funding for Neuroscience Research (<b>NEURON</b>), and the Human Brain Project (<b>HBP</b>), which is also putting in place the <b>EBRAINS</b> research infrastructure. At global level, collaborative work is ongoing with the World Health Organization and Organisation for Economic Co-operation and Development on strengthening the knowledge base for interventions</p>

on mental health and supporting countries to improve their capacity to address mental health challenges.

The initiatives have addressed research questions related to determinants of mental health, neurodegenerative diseases, and neurodevelopmental disorders. They have identified major drivers, including genetic susceptibility, environmental risk factors, and limits of existing care and health systems. The improved understanding, however, needs to translate better into the development of new treatments. Simultaneously, prevention strategies have been identified as the most promising way to reduce the high personal, familial, societal, clinical, and economic costs of brain disorders.

In 2019, and under the Coordination and Support Action (CSA) 'European Brain Research Area' (**EBRA**), the three initiatives JPND, NEURON and HBP/EBRAINS started discussing ways to find operational synergies, identify gaps, and foster alignment across European and global brain initiatives. In 2022, EBRA delivered a common research agenda, as input for a future strategic research and innovation agenda in brain health. Additionally, HBP initiated a discussion in the international community to formulate the scientific vision for the next decade of digital brain research, with particular focus on digital tools enabling progress in brain medicine.

**These initiatives have now acquired an invaluable experience and trust, strongly supported by the European Commission and Member States, and encompassing significant non-European international partners.**

Already in 2019, Member States (MS) and Associated Countries (AC) expressed strong interest to develop a European partnership on Brain Health, to be included in the 1<sup>st</sup> Strategic Plan (2021-24). With several initiatives still running, and other priority partnerships in the field of health to be launched, it was agreed to postpone the brain health partnership to the 2<sup>nd</sup> Strategic Plan<sup>2</sup>. In 2022, interest for such a partnership was restated and a preparatory CSA was requested in the Health cluster 2023-24 work programme. The CSA, expected to start in Q4 2023, should notably develop a strategic research and innovation agenda, paving the way to the brain partnership. The CSA will also be tasked with ensuring a broad geographical representation of European countries and to further pursue efforts already undertaken to strengthen the participation of widening countries.

**Seizing the momentum and capitalising on cutting-edge research will unleash a powerful innovation force and create a new ecosystem for brain research, to be consolidated in an ambitious partnership on brain health, strengthening the position of European brain health research.**

Objectives and expected impacts	The objectives are to i) find cures for brain disorders, ii) enable early diagnosis for early, personalised treatments that are affordable and accessible to everyone, iii) promote evidence-based prevention at
---------------------------------	--



	<p>individual and community level, and iv) optimise the clinical management of affected persons, including the identification and diffusion of best practices and standards, structures and care.</p> <p>These are framed within the wider context of the United Nation's <b>Sustainable Developmental Goal</b> target 3.4 on non-communicable diseases and mental health; the World Health Organization's response to the burden posed by neurological and mental disorders; the <b>Healthier Together - EU Non-Communicable Diseases Initiative</b>, which includes a focus area on 'Mental health and neurological disorders'; and the Commission Communication on a <b>comprehensive approach to mental health</b>, adopted on 7 June 2023<sup>3</sup>.</p> <p>By further structuring the brain research and innovation area in Europe, major <b>expected impacts</b> of the partnership are the translation of research results into innovative products for earlier, more accurate diagnosis and more effective treatments, more adapted and successful prevention and care strategies, including the identification of best practices, and better implementable public health policies.</p> <p>The partnership will thereby also contribute to the <b>European Health Union</b> by supporting one important goal of the revision of the pharmaceutical legislation: addressing unmet medical needs. It will also feed into the <b>European Care Strategy for caregivers and care receivers</b> that aims to ensure high quality, affordable and accessible care services for all ages.</p> <p>Steps include:</p> <ul style="list-style-type: none"> <li>• establishment of a common roadmap with all stakeholders</li> <li>• delivery of efficient strategies for industry-academia collaborations</li> <li>• facilitation of data sharing and access to unique infrastructures</li> <li>• integrating MS that do not yet have a specific brain health agenda</li> <li>• strengthened collaboration with international initiatives<sup>4,5</sup></li> <li>• further internationalisation, especially towards American and Asian countries</li> <li>• better consideration of sex and gender aspects in research.</li> </ul>
Necessity test: rationale for a	The extent of the challenges, including the rapidly growing impact of the ageing European population or its declining mental health <sup>6</sup> and the

European Partnership	<p>complexity of brain health, require a highly coordinated support. A sustainable, holistic research and innovation strategy in brain health is necessary, which goes beyond traditional calls from the EU Framework Programmes and national programmes. The existing brain research initiatives have clearly demonstrated that bringing together all stakeholders (including Ministries of Research, research organisations, councils to Ministries of Health, health agencies, patient associations and health economists) to address the same specific issue of improving brain health can bring tremendous momentum and added value, leading to progress in research and adaptation of care. The ERANET programmes co-funded by the EC have significantly boosted the funding commitments of the participating MS and AC. It is paramount to ensure much-needed overall coordination, to prevent the deconstruction of the existing ecosystems, while there are still so many unmet brain health needs to answer. Cross-fertilisation and synergies between existing initiatives supported by the EU Framework Programmes and MS would be best ensured by bringing them under one single umbrella, also ensuring economies of scale. <b>This new partnership will seize the unique momentum and accelerate the creation of the largest competitive European and global collaboration, essential to improve brain health by motivating and mobilising all the stakeholders under a common and strong transnational banner.</b></p>
Relevant for the following parts of Horizon Europe	<p>Pillar II 'Global Challenges and European Industrial Competitiveness'</p> <p><input checked="" type="checkbox"/> Cluster Health</p>
Currently identified links with other partnership candidates / Union programmes	<p>Under Cluster 1 (Health) links include the <b>public-public (co-funded) partnerships</b>: Rare diseases; Personalised medicine; Transforming health and care systems; ERA for Health; and the <b>public-private institutionalised partnership</b> Innovative Health Initiative (IHI) and the EIT Health.</p> <p>Under Cluster 2, links relate to socio-economic transformations that contribute to inclusion and growth, as well as to how culture and arts can contribute to mental health and wellbeing.</p> <p>There are also links with the Cancer Mission e.g. regarding how to ensure good mental health and wellbeing of cancer patients and survivors.</p> <p>Relevant Union programmes include • <b>EU4Health</b>, which supports the Healthier Together – EU Non-Communicable Diseases Initiative (with a focus area on 'Mental health and neurological disorders'), or the European Health Data Space (with EBRAINS research infrastructure participating as a partner in a pilot project); or the • <b>Digital Europe Programme</b>, which contributes to the deployment of a European common health data space.</p>
Does the proposed partnership build on currently active ones?	<p>The constant improvement and growth of brain health research has been catalysed by several EU funded projects and initiatives, of which the following are currently active:</p> <p><b>ERA-NETs</b>: JPCofuND2 (ending 31/12/24); NEURON Cofund2 (ending 31/12/25); <b>FET Flagship</b>: Human Brain Project (HBP; ending 30/09/23)</p> <p>These initiatives have paved the way for an ambitious partnership,</p>

*ProteoCure Cost Action Network Opportunities for Funding and Collaboration*  
*October 30, 2023 10:00 – 12:30 hours*



	<p>building trust and attracting new participants. They also facilitated the initiatives management, complementing national “virtual common funding pots” with a real common pot, allowing gap-filling and national budget mobilisation.</p>
Expected type and composition of partners	<p>This partnership will benefit from the partners already participating in the existing brain research initiatives, and will be primarily composed of institutions and agencies that fund brain research in Europe. It will also involve other stakeholders such as patient organisations, policy makers, researchers, health care providers and practitioners, citizens, regulators and industry representatives. The governance of the partnership aims to be light, efficient, and flexible to accommodate all participants.</p> <p>At <b>country level</b>, the existing partnerships have already enrolled many MS, AC and 3<sup>rd</sup> countries. JPND has 30 participating countries, while NEURON has 23, with many countries participating in both initiatives. The new partnership should further enlarge to additional <b>national research funding agencies</b>. Collaborations with the USA are being strengthened, while further extension to EU13 and Asian countries is in progress. At <b>researchers’ level</b>, the existing initiatives have gained recognition, establishing a visible European brain research area.</p> <p>This unique experience and recognition have allowed <b>institutional organisation and agencies</b> to yearly earmark funding to participate in these initiatives. Several initiatives have enrolled <b>patient groups, carers, and the general public</b> in the prioritisation and the evaluation of their actions, and this will be strengthened. The partnership also aims to increase the participation of <b>private and industry stakeholders</b> through other existing initiatives like the IHI, but also by attracting <b>SMEs</b> involved in care and treatment innovation. <b>Regulators</b> from European and state agencies, OECD and other major players in the field of policy regulations will also be encouraged to participate. Collaboration with <b>non-profit and non-governmental organisations</b> will also be sought.</p> <p>Additionally, efforts will be made to boost the exploitation of research and innovation results by reaching out to <b>other national ministries, in charge of e.g. health, industry or employment policies</b>.</p>
Contributions and commitments expected from partners	<p>Using the overall contributions (national + EU funding) of the main partnerships (JPND, NEURON, HBP) under Horizon 2020, a sum of €77 million/year is currently observed: • JPND: €66 million over 7 years = €9 million/year • NEURON: €49 million over 7 years = €7 million/year •HBP: €607 million over 10 years = ~€ 61 million/year</p> <p>A rough 25% increase of brain research investments for the new partnership would allow Europe to remain competitive on the global scene.</p>
Currently envisaged implementation mode(s).	<p><input type="checkbox"/> Co-programmed European Partnership</p> <p><input checked="" type="checkbox"/> Co-funded European Partnership</p> <p><input type="checkbox"/> Institutionalised European Partnership</p> <p style="padding-left: 20px;"><input type="checkbox"/> Article 185</p> <p style="padding-left: 20px;"><input type="checkbox"/> Article 187</p> <p><input type="checkbox"/> EIT-KIC</p>

ProteoCure Cost A  
October 30, 2023 10:0

Justification of the implementation mode	The co-funded mode of collaboration with the EC will offer a high and attractive European and global visibility. An invaluable leverage effect in the amount of funds mobilised by the participants is to be expected, as illustrated in the Horizon 2020 co-funded partnerships.
Proposed starting year	2025



## PARTNERS



### European Brain Council EBC




The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies as well as industries. Established in March 2002, its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe.

165 million Europeans are living with a brain disorder, causing a global cost (direct and indirect) exceeding 800 billion euros for the National Health budgets. EBC's main action areas are:

- Fostering cooperation with its members organisations
- Promoting dialogue between scientists, industry and society
- Interacting with the European Commission, the European Parliament and other relevant international institutions
- Raising awareness and promoting education on the brain
- Disseminating information about brain research and brain diseases in Europe.

**ProteoCure Cost Actik**  
October 30, 2023 10:00 -

[www.braincouncil.eu](http://www.braincouncil.eu)



### The EU Joint Programme JNPD



The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases.

The ultimate goal of JPND is to find cures for neurodegenerative diseases and to enable early diagnosis for early targeted treatments. However, it is not possible to give definitive predictions on how long this might take to happen.

<http://www.neurodegenerationresearch.eu/>




**Neuron**  
**ERA-NET NEURON**



The ERA-NET NEURON supports basic, clinical and translational research in the diverse fields of disease-related neuroscience. Ministries and funding organisations across Europe, Israel, Turkey and Canada have joined forces to conquer diseases of the brain and the nervous system. According to estimates by the World Health Organisation, more than one billion people suffer from them. Brain diseases are major causes for impaired quality of life. They produced costs of € 800 billion in 2010 and are an increasingly heavy burden on our society. Not just for the patients, but for their families too. In many cases the underlying mechanisms are still not well understood and no curative treatment is available. Thus, neuroscience research and its translation into diagnostic and therapeutic measures are of highest priority for the well-being of patients and their families. The ERA-NET NEURON aims to support research directed at a better understanding of brain diseases and their progression in order to pave the way for new or improved routes for diagnosis and therapy.

<https://www.neuron-eranet.eu/>



**The Human Brain Project**  
**HBP**



The Human Brain Project (HBP) is building a research infrastructure to help advance neuroscience, medicine and computing. It is one of the two largest scientific projects ever funded by the European Union.

The 10-year Project began in 2013 and directly employs some 500 scientists at more than 100 universities, teaching hospitals and research centres across Europe.

Six ICT research Platforms form the heart of the HBP infrastructure: Neuroinformatics (access to shared brain data), Brain Simulation (replication of brain architecture and activity on computers), High Performance Analytics and Computing (providing the required computing and analytics capabilities), Medical Informatics (access to patient data, identification of disease signatures), Neuromorphic Computing (development of brain-inspired computing) and Neurorobotics (use of robots to test brain simulations).

The HBP also undertakes targeted research and theoretical studies, and explores brain structure and function in humans, rodents and other species. In addition, the Project studies the ethical and societal implications of HBP's work.

<https://www.humanbrainproject.eu>





THIRD PARTIES

---



*ProteoCure Cost Action Network Opportunities for Funding and Collaboration*  
*October 30, 2023 10:00 – 12:30 hours*



**Few words on the Missions...**





Horizon Europe Work programme (2023-24) - General introduction (draft)  
English (1.49 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - EU Missions (draft)  
English (2.2 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Cluster 1 (draft)  
English (2.64 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Cluster 2 (draft)  
English (1.86 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Cluster 4 (draft)  
English (4.8 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Cluster 5 (draft)  
English (4.83 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Cluster 6 (draft)  
English (6.25 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - European Innovation Ecosystems (draft)  
English (963.81 KB - PDF)

Download



Horizon Europe Work programme (2023-24) - MSCA (draft)  
English (1.4 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Infrastructures (draft)  
English (1.83 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - WIDERA (draft)  
English (1.75 MB - PDF)

Download



Horizon Europe Work programme (2023-24) - Annexes (draft)  
English (1 MB - PDF)

Download

# Horizon Europe work programmes

What work programmes are, what they cover, download available Horizon Europe work programmes.

## PAGE CONTENTS

[Work programmes under Horizon Europe](#)

[View available work programmes](#)

## Work programmes under Horizon Europe

Work programmes set out funding opportunities under Horizon Europe.

One specific programme under Horizon Europe is implemented through the following:

The main work programme

- Marie Skłodowska-Curie actions and research infrastructures under Pillar I
- all clusters under Pillar II
- European innovation ecosystems under Pillar III
- the part widening participation and strengthening the European Research Area

Other work programmes cover

- European Research Council (ERC)
- Joint Research Centre (JRC)
- European Innovation Council (EIC)

A significant part of Pillar II of Horizon Europe will be implemented through institutionalised partnerships, particularly in the areas of Mobility, Energy, Digital and Bio-based economy, which will also have separate work programmes.

The activities of the [European Institute of Technology \(EIT\)](#) are set out in separate programming documents.

[https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes\\_en](https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes_en)





# The R&I Missions

## R&I Missions

**Connecting to citizens:** Missions will relate EU's research and innovation to society and citizens' needs, with strong visibility and impact

A mission will consist of a portfolio of actions intended to achieve **a bold and inspirational as well as measurable goal** within a set timeframe, with impact for science and technology, society and citizens that goes beyond individual actions.

Horizon Europe proposal defines mission characteristics and criteria

Specific missions will be **co-designed with Member States, stakeholders and citizens** and programmed within the Global Challenges and Industrial Competitiveness pillar (drawing on inputs from other pillars)

**About 10% Budget of Pillar-II** will be devoted to Missions + MMSS contributions & other programmes, initiatives or sources!

Adaptation to climate change, including societal transformation

Mission areas starting in 2021...

Healthy oceans, seas, coastal and inland waters



**Mission areas**



Climate-neutral and smart cities



Soil health and food

EC is proposing a new Mission on the New EU Bauhaus starting by 2025... BUT it is under negotiation with the MS!

## Mission boards

Information about the mission areas and the people chairing the mission boards.

### Connie Hedegaard

Adaptation to Climate Change including Societal Transformation



Served as European Commissioner for Climate Action from 2010 to 2014, during which time she led the negotiations towards the adoption of the EU 2030 Climate and Energy Framework and represented the EU in the international climate negotiations.

[Read the biography](#)

### Walter Ricciardi

Cancer



In October 2019 Professor Ricciardi replaced the originally named chair, Professor Harald zur Hausen.

[Read the biography](#)

### Pascal Lamy

Healthy Oceans, Seas, Coastal and inland Waters




Former European Commissioner for Trade and Director General of the World Trade Organisation from 2005-2013.

[Read the biography](#)

### Hanna Gronkiewicz-Waltz

Climate-Neutral and Smart Cities



Former chair of the Central Bank of Poland, also served as Mayor of Warsaw.

[Read the biography](#)

### Cees Veerman

Soil health and Food



Dutch Minister of Agriculture from 2002 to 2007 and was also President of the EU Council of Agriculture Ministers.

[Read the biography](#)

<https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3813>

## Register of Commission Expert Groups and Other Similar Entities

Home Expert Groups Meetings Members Calls for application News

Register of Commission Expert Groups > Expert Groups > Details

GROUP | E03813

Commission expert group: Mission Board for Cancer Mission (E03813)

ACTIVE

Subscribe to this group

Print as PDF

Details

Additional Information

Meetings

Subgroups

Members

Statistics

#### Abbreviation

-

#### Lead DG

▶ RTD - DG Research and Innovation

#### Type

▶ Informal

▶ Temporary

#### Mission

According to Article 7 (3) of the Specific Programme implementing Horizon Europe : the task of the Mission Boards shall be to advise the Commission upon all or some of the following aspects: (a) the identification and design of one or more missions in the respective mission area according to the provisions and criteria set out in Article 8 of Regulation (EU) 2021/695; (b) content of work programmes and their revision as needed for achieving the mission objectives, with input from stakeholders and, where relevant, the general public; (c) the characteristics of project portfolios for missions; (d) adjustment actions, or termination, if appropriate, based on implementation assessments according to the defined objectives of the mission; (e) the selection of independent external experts in accordance with Article 49 of Regulation (EU) 2021/695, briefing of these independent external experts and evaluation criteria and their weighting; (f) framework conditions which help achieve the objectives of the mission; (g) communication, including on the performance and the achievements of the mission; (h) policy coordination between relevant actors at different levels, in particular regarding synergies with other Union policies; (i) key performance indicators. Within the frame of these tasks, the Mission Board shall focus more specifically on points (f), (g), (h) and (i).

#### Policy Area

▶ Public Health

▶ Research and Innovation

#### Associated DG

▶ SANTE - DG Health and Food Safety

#### Scope

▶ Broad

#### Task

▶ Assist the Commission in the preparation of legislative proposals and policy initiatives



# Mission boards

Information about the mission areas and the people chairing the mission boards.

## Register of Commission Expert Groups and Other Similar Entities

[Home](#) [Expert Groups](#) [Meetings](#) [Members](#) [Calls for application](#) [News](#)

[Register of Commission Expert Groups](#) > [Expert Groups](#) > [Details](#)

GROUP | E03813

Commission expert group: Mission Board for Cancer Mission (E03813)

ACTIVE

Subscribe to this group  
Print a PDF

Details Additional Information Meetings Subgroups **Members** Statistics

**Abbreviation**  
-

**Lead DG**  
▶ RTD - DG Research and Innovation

**Type**  
▶ Informal  
▶ Temporary


**Mission**  
According to Article 7 (3) of the Specific Programme implementing Horizon Europe : the task of the Mission Boards shall be to advise the Commission upon all or some of the following aspects: (a) the identification and design of one or more missions in the respective mission area according to the provisions and criteria set out in Article 8 of Regulation (EU) 2021/695; (b) content of work programmes and their revision as needed for achieving the mission objectives, with input from stakeholders and, where relevant, the general public; (c) the characteristics of project portfolios for missions; (d) adjustment actions, or termination, if appropriate, based on implementation assessments according to the defined objectives of the mission; (e) the selection of independent external experts in accordance with Article 49 of Regulation (EU) 2021/695, briefing of these independent external experts and evaluation criteria and their weighting; (f) framework conditions which help achieve the objectives of the mission; (g) communication, including on the performance and the achievements of the mission; (h) policy coordination between relevant actors at different levels, in particular regarding synergies with other Union policies; (i) key performance indicators. Within the frame of these tasks, the Mission Board shall focus more specifically on points (f), (g), (h) and (i).

**Policy Area**  
▶ Public Health  
▶ Research and Innovation

**Associated DG**  
▶ SANTE - DG Health and Food Safety

**Scope**  
▶ Broad

**Task**  
▶ Assist the Commission in the preparation of legislative proposals and policy initiatives



<https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3813>

Details Additional Information Meetings Subgroups **Members** Statistics

### Type A - Individual expert appointed in his/her personal capacity (14)

Name	Nationality	Professional Title	Membership Status
ARABADJIEV Jeli azko	Bulgaria	Associate Professor Doctor	Member
CHOMIENNE Christine	France	Dr.	Member
DRURY Amanda	Ireland	Dr.	Member
FRÖBE Ana	Croatia	Prof.	Member
GUNTHER Pernilla	Sweden	Ms.	Member
MAHER Nevenka	Slovenia	Dr.	Member
PALM Kaia	Estonia	Ms.	Member
PIETERS Rob	Netherlands	Prof.	Member
SVOBODA Marek	Czech Republic	Mr.	Member
TOLEDO CHÁVARRI Ana	Spain	Ms.	Member
TOLMA Eleni	Cyprus	Dr.	Member
TSAGKARIS Christos	Greece	Dr.	Member
WEIDERPASS VAINIO Elisabete	Finland	Prof. Dr.	Member
WESTPHALEN Benedikt	Germany	Dr.	Member

## Missions in Horizon Europe

What missions are, the areas they will focus on, studies and reports that led to this approach, how to get involved and relevant events.

### PAGE CONTENTS

[What are missions?](#)

[Making missions happen](#)

[How to get involved](#)

[Contact](#)

[Latest](#)

[Related links](#)

### What are missions?

Partly inspired by the Apollo 11 mission to put a man on the moon, European research and innovation missions aim to deliver solutions to some of the greatest challenges facing our world.

They are an integral part of the Horizon Europe framework programme beginning in 2021.

Each mission is a mandate to solve a pressing challenge in society within a certain timeframe and budget.

[A wide range of studies and reports](#) informed this approach.



#### Missions will

- be bold, inspirational and widely relevant to society
- be clearly framed, targeted, measurable and time-bound
- establish impact-driven but realistic goals
- mobilise resources
- link activities across different disciplines and different types of research and innovation
- drive a systemic change and transform landscapes rather than fix problems in existing ones
- make it easier for citizens to understand the value of investments in research and innovation

[https://ec.europa.eu/info/horizon-europe-next-research-and-innovation-framework-programme/missions-horizon-europe\\_en](https://ec.europa.eu/info/horizon-europe-next-research-and-innovation-framework-programme/missions-horizon-europe_en)

### Citizen events and specialised missions conferences

Date ↕	Mission ↕	Country ↕	Event ↕	Information ↕
12-15/10/2020	soil	Belgium	<a href="#">Mission session - European Week of Regions and Cities</a>	
13/10/2020	cancer	Germany	HL Cancer summit - citizen session (tbd)	
9-10/10/2020	cities	Greece	<a href="#">Visioning MED 2020+ - Mediterranean in Transition</a>	<a href="#">Website</a>
7-8/10/2020	soil	Portugal	EIP- AGRI seminar Healthy soils for Europe - citizen session (tbd)	
28-29/09/2020	cities	Finland	Sustainable Digital Built Environment Congress - citizen panel (tbd)	
22-24/09/2020	all missions	multinational	<a href="#">R&amp;I days</a>	
2-5/09/2020	cities	Romania	Smart Transport Summit citizen panel (tbd)	

# What is in Missions for research and industry?



## Adaptation to Climate Change



Improving the performance of nature based solution and develop protocols for their implementation



Increasing and facilitating uptake of nature based solutions through the use of public procurement. Pre-Commercial Procurements and Public Procurement of Innovation



## Cancer



Understand healthy versus cancer cells at individual and population level;



Develop non-invasive cancer screening and detection methodologies.



## Water



Increase our knowledge of our oceans and water life, including DNA sequencing to unravel microbiomes of marine and coastal ecosystems



Innovative, affordable and scalable technologies for remote and accurate monitoring of fishing activities

**Mission: Cancer** ..... 29

**Call - Research and Innovation actions supporting the implementation of the Mission on Cancer** ..... 31

Conditions for the Call ..... 31


HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients. .... 32

HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioural change ..... 35

HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics ..... 36

HORIZON-MISS-2023-CANCER-01-04: Improving the quality of life for childhood cancer patients in underserved regions ..... 37

Opening: 12 Jan 2023  
Deadline(s): 12 Apr 2023



**HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.**

<b>Specific conditions</b>	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of between EUR 7.00 and 12.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 36.68 million.
<i>Type of Action</i>	Research and Innovation Actions



## The research and innovation community platform

Connecting researchers across borders and disciplines. Take part in events, access exclusive content, widen your network.

Home **Events** Community How it works

REWATCH

### EU Missions info days

The event aims to inform potential applicants about the new topics included in the EU Missions work programme 2023

17 January 2023 - 18 January 2023

09:00 (GMT+01:00)



1335 members are attending this event

Log in

Register now

### About the event

You can watch the recordings of the event on the [Programme](#) page.

Are you interested in funding opportunities for projects helping to reach the [EU Missions goals](#) in the areas of health, climate and the environment? Would you like to contribute to bring concrete solutions to some of the greatest challenges facing our society?

Join us online and learn more about the new calls in the Missions' part of the main Work Programme 2023 under Horizon Europe for each mission:

- Adaptation to Climate Change Mission
- Cancer Mission
- 100 Climate-Neutral and Smart cities by 2030 Mission
- Restore our Ocean and Waters by 2030 Mission
- A Soil Deal for Europe Mission

The EU Missions part of the main work programme 2023 under Horizon Europe contains new mission specific calls and topics to support the full implementation of missions according to their implementation plans. In addition, three joint calls created to favour synergies across missions and achieve their impacts will be presented.

## Synergies among missions

- Under discussion (also taking account administrative practicability): Joint topics with Missions
- **Cancer:** aspects of soil pollution, exposure pathways and impact on human health
- **Oceans:** reduction loss of nutrients in agriculture and prevent water contamination from nutrients
- **Oceans and Climate Adaptation:** Integrated approach to landscape, soil and water management; boosting landscape water retention capacity and resilience to climate change impacts



HORIZONTE  
EUROPA

Jornada Misiones Horizonte Europa: Novedades y Convocatorias 2023

Agenda Inscripción Acceso a grabaciones y presentaciones

Mayo  
17  
Comienza: 10:00

Webinario online  
Evento terminado

Añade al calendario

### Descripción:

Se trata de una jornada informativa online sobre las misiones de Horizonte Europa y las convocatorias en el Programa de Trabajo 2023.


La jornada se iniciará a las 10:00 horas con intervenciones iniciales centradas en el estado de desarrollo de las misiones y su futuro próximo. A continuación, los participantes se podrán unir a cada una de las cinco sesiones paralelas que se van a organizar y donde se explicará en detalle el estado de desarrollo e implementación de cada misión, y en el caso de haber convocatorias abiertas, se profundizará en el contenido del Programa de Trabajo 2023, mostrando las oportunidades de participación en proyectos colaborativos de I+D+I:

- Misión Cáncer (Sala Cáncer).
- Misión Restaurar nuestros Océanos y Aguas (Sala Océanos).
- Misión Adaptación al Cambio Climático (Sala Clima).
- Misión Ciudades inteligentes y climáticamente neutras (Sala Ciudades).
- Misión Un pacto europeo sobre el Suelo (Sala Suelos).

**Few words on the MSCA actions...**



# Horizon Europe today: An evolution, not a revolution?



© European Union 2021

# Horizon Europe work programmes

What work programmes are, what they cover, download available Horizon Europe work programmes.

## PAGE CONTENTS

[Work programmes under Horizon Europe](#)

[View available work programmes](#)

## Work programmes under Horizon Europe

Work programmes set out funding opportunities under Horizon Europe.

One specific programme under Horizon Europe is implemented through the following:

The main work programme

- Marie Skłodowska-Curie actions and research infrastructures under Pillar I
- all clusters under Pillar II
- European innovation ecosystems under Pillar III
- the part widening participation and strengthening the European Research Area

Other work programmes cover


- European Research Council (ERC)
- Joint Research Centre (JRC)
- European Innovation Council (EIC)

A significant part of Pillar II of Horizon Europe will be implemented through institutionalised partnerships, particularly in the areas of Mobility, Energy, Digital and Bio-based economy, which will also have separate work programmes.


The activities of the [European Institute of Technology \(EIT\)](#) are set out in separate programming documents.


[https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes\\_en](https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/horizon-europe-work-programmes_en)






 **Horizon Europe Work programme (2023-24) - General introduction (draft)** [Download](#)   
English (1.49 MB - PDF)

 **Horizon Europe Work programme (2023-24) - EU Missions (draft)** [Download](#)   
English (2.2 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 1 (draft)** [Download](#)   
English (2.64 MB - PDF)


 **Horizon Europe Work programme (2023-24) - Cluster 2 (draft)** [Download](#)   
English (1.86 MB - PDF)



 **Horizon Europe Work programme (2023-24) - Cluster 4 (draft)** [Download](#)   
English (4.8 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Cluster 5 (draft)** [Download](#)   
English (4.83 MB - PDF)



 **Horizon Europe Work programme (2023-24) - Cluster 6 (draft)** [Download](#)   
English (6.25 MB - PDF)

 **Horizon Europe Work programme (2023-24) - European Innovation Ecosystems (draft)** [Download](#)   
English (963.81 KB - PDF)

 **Horizon Europe Work programme (2023-24) - MSCA (draft)** [Download](#)   
English (1.4 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Infrastructures (draft)** [Download](#)   
English (1.83 MB - PDF)

 **Horizon Europe Work programme (2023-24) - WIDERA (draft)** [Download](#)   
English (1.75 MB - PDF)

 **Horizon Europe Work programme (2023-24) - Annexes (draft)** [Download](#)   
English (1 MB - PDF)

# The MSCA have 5 main actions

Overall message in Horizon Europe:  
**continuation**



## Doctoral Networks

**implement doctoral programmes** (including joint doctorates and industrial doctorates) **by international partnerships** of organisations from different sectors. They train highly-skilled doctoral candidates, stimulate their creativity, enhance their innovation capacities and boost their employability in the long-term.



## Postdoctoral Fellowships

**support researchers' careers and foster excellence in research and innovation.** Researchers holding a PhD can carry out their research activities, acquire new skills and develop their careers abroad, whilst developing competences in non-academic sectors and working within interdisciplinary teams.


## Staff Exchanges

**encourage short-term international and inter-sectoral exchanges of research and innovation staff** through sustainable, collaborative projects in Europe and beyond. By doing so, they enhance knowledge and skills transfer and increase organisations' research and innovation capacities.



## MSCA and Citizens

**brings research and researchers closer to children, families and the public at large** through the European Researchers' Night - the annual research communication and promotion event taking place at the end of September across EU Member States and Horizon Europe Associated Countries.



## COFUND

**co-finances regional, national and international doctoral and postdoctoral programmes for researchers' training and career development.** The COFUND action spreads MSCA's best practices by setting high standards and excellent working conditions, and boosts training and international, interdisciplinary and inter-sectoral mobility.



<https://marie-sklodowska-curie-actions.ec.europa.eu/>

CLICK HERE





# Who do the MSCA support?

<b>Researchers</b>	<b>Actions available</b>
Researchers without a PhD degree	Doctoral Networks Staff Exchanges COFUND-DP
Researchers with a PhD degree	Postdoctoral Fellowships Staff Exchanges COFUND-PP
Other staff (Research managers, technicians, etc.)	Staff Exchanges



# MSCA WP 2023-2024 structure

<b>Training and Mobility Actions</b>	<b>MSCA Doctoral Networks</b>	<b>MSCA Postdoctoral Fellowships</b>	<b>MSCA Staff Exchanges</b>	<b>MSCA COFUND</b>	<b>MSCA and Citizens</b>
	Call 2023	Call 2023	Call 2023	Call 2023	Call 2023
	Call 2024	Call 2024	Call 2024	Call 2024	
<b>Coordination and Support Actions</b>	<b>MSCA Support</b>				
	MSCA Feedback To Policy 2023	Trans-national cooperation among MSCA NCPs 2024	MSCA International Cooperation 2024	MSCA for Researchers at Risk 2024	
<b>Other Actions (not subject to calls for proposals)</b>	<b>Grants Grants not subject to calls for proposals</b>				
	MSCA Presidency events (ES 2023, BE 2024)	Support to the Marie Curie Alumni Association		MSCA Special Needs Allowances to Horizon 2020 legacy projects	
	<b>Procurement:</b> Public Procurement for Events and Outreach				
	<b>Other budget implementation instruments:</b> External expertise				

# MSCA Doctoral Networks

- **Multi-beneficiary action** to set up innovative **doctoral programmes**, including:
  - **Industrial Doctorates**
    - Training in academia and industry
    - Joint supervision
  - **Joint Doctorates**
    - Joint collaborations leading to a joint/double/multiple doctoral degree
    - Joint selection, supervision and governance structure
    - Pre-agreement for joint degrees required
- **Target group**
  - **doctoral candidates**, i.e. researchers without a doctoral degree at the date of the recruitment; mandatory enrolment in a doctoral programme in at least 1 EU MS/AC (at least 2 for Joint Doctorates)
  - **researchers apply to vacancies published** by the institutions participating in the projects
- **Focus on career development plan, supervision, training:** research and transferable skills
- **Who applies?**
  - **consortia** of universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors; each beneficiary to recruit at least 1 researcher
  - at least **three independent legal entities**, each established in a different MS or AC; minimum of 1 beneficiary from a MS (on top of this minimum, any entity from any third country can join)

# MSCA Doctoral Networks

- **Size**

- Up to **540 person-months (for all configurations including standard DN)**

- **Duration**

- **Programme:** max. 48 months, except max 60 months for joint doctorates
- **Fellow:** between 3 and 36 months, except up to 48 months for joint doctorates
- **Secondments:** up to 1/3 of the fellowship duration for standard DN, no limitation for industrial and joint doctorates
- **Industrial doctorates:** at least 50% of the fellowship in the non-academic sector; can be in the same country as the academic host organisation

- **Call**

- **2023: 30 May 2023 – 28 Nov. 2023**: 434,8 M€
- **Resubmission restrictions** applying as of 2022 for applications receiving a score **below 80%** in the previous Horizon Europe call

# MSCA Doctoral Networks: award criteria

Excellence	Impact	Quality and efficiency of the implementation
Quality and pertinence of the project's research and innovation objectives	Contribution to structuring doctoral training at European level and strengthening European innovation capacity	Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages
Soundness of the proposed methodology	Credibility of the measures to enhance the career perspectives of researchers and contribution to their skills development	Quality, capacity and role of each participant, including hosting arrangements and extent to which the consortium as a whole brings together the necessary expertise
Quality and credibility of the training programme	Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities	
Quality of the supervision	The magnitude and importance of the project's contribution to the expected scientific, societal and economic impacts	
<b>50%</b>	<b>30%</b>	<b>20%</b>



# MSCA Doctoral Networks – Unit contributions

Contributions for recruited researchers Per person-month					Institutional unit contributions Per person-month	
Living allowance	Mobility allowance	Family allowance (if applicable)	Long-term leave allowance (if applicable)	Special needs allowance (if applicable)	Research, training and networking contribution	Management and indirect contribution
EUR 3 400	EUR 600	EUR 660	EUR 4 000 x % covered by the beneficiary	Requested unit <sup>1</sup> x (1/number of months)	EUR 1 600	EUR 1 200

<sup>1</sup>The pre-defined categories are as follows: EUR 3 000, EUR 4 500, EUR 6 000, EUR 9 500, EUR 13 000, EUR 18 500, EUR 27 500, EUR 35 500, EUR 47 500 and EUR 60 000.

# MSCA Postdoctoral Fellowships

- **Mono-beneficiary action** to support **postdoctoral research** and careers
- **Two types of Fellowships:**
  - **European Fellowships:** researchers of any nationality moving within or coming to Europe
  - **Global Fellowships:** European nationals or long-term residents in Europe to do research abroad
- Continue funding **all research domains** including areas covered by **EURATOM**
- Improved guidance towards **career development** (plan & supervision)
- **Recruited researchers**
  - **Mobility rule** applies! No more than 12 months in the last 36 months
  - In possession of **PhD** degree at the call deadline
  - **Up to 8 years** of research experience after PhD at the call deadline, with **exceptions:**
    - Years **outside research, career breaks, work outside Europe** (for those reintegrating to Europe will not be counted)

# MSCA Postdoctoral Fellowships

- **Who applies?**

- **Single legal entity** established in an EU Member State or HE Associated country (specific conditions for EURATOM areas), **jointly** with the researcher

- **Duration**

- **European Fellowships: 12-24 months**
- **Global Fellowships: 24-36 months** (12-24 outgoing + 12 months mandatory return phase in Europe)
- **Secondments worldwide up to 1/3 of the fellowship** duration (outgoing phase for Global Fellowships)
- Optional **additional placement of up to 6 months in a non-academic** European organization, at the end of the fellowship (EF/GF) to build bridges between sectors

- **Seal of Excellence** continues

- **Call**

- **2023:** 12 Apr 2023 – 13 Sep. 2023 : 260,47 M€
- Restrict **resubmissions** with score less than 70% to the following year (as of 2022)

# MSCA Postdoctoral Fellowships – Unit contributions

Contributions for recruited researchers Per person-month					Institutional unit contributions Per person-month	
Living allowance	Mobility allowance	Family allowance (if applicable)	Long-term leave allowance (if applicable)	Special needs allowance (if applicable)	Research, training and networking contribution	Management and indirect contribution
EUR 5 080	EUR 600	EUR 660	EUR 5 680 x % covered by the beneficiary	Requested unit <sup>1</sup> x (1/number of months)	EUR 1 000	EUR 650

<sup>1</sup>The pre-defined categories are as follows: EUR 3 000, EUR 4 500, EUR 6 000, EUR 9 500, EUR 13 000, EUR 18 500, EUR 27 500, EUR 35 500, EUR 47 500 and EUR 60 000.



# MSCA Staff Exchanges

- **Multi-beneficiary action** to support **collaborative R&I activities through staff exchanges**
- **Target group:** any type of staff at any stage of career contributing to research activities (researchers, administrative & managerial staff, technicians, infrastructure operators...)
- **Focus** on international, inter-sectoral, interdisciplinary secondments leading to knowledge transfer between participating organisations and strengthening long-term collaborations. Emphasis on the added-value of the collaboration.
- **Who applies?**
  - **consortia** of universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors
  - **at least three independent legal entities in three different countries**, two of which established in a different EU Member State or Horizon Europe Associated Country.
  - If all participating organisations are from the same sector (i.e. either only academic or only non-academic), there must be at least one organisation from a non-associated Third Country

# MSCA Staff Exchanges

- **Size: up to 360 person-months**
- **Duration**
  - **Programme:** max. 48 months (no change)
  - **Secondments:** between countries worldwide and between independent entities; **1-12 months** per staff member (independently of the number of organisations the staff is seconded to);
    - Interdisciplinary secondments in the same sector possible within Europe (max 1/3 of the total person-months);
- Most international action under MSCA
- **Call**
  - **2022:** 6 Oct 2022- 8 Mar 2023; 77,5 M€
  - **2023:** 5 Oct 2023- 28 Feb 2024; 78,5 M€

# MSCA Staff Exchanges – Unit contributions

<b>Contributions for seconded staff members</b> Per person-month		<b>Institutional unit contributions</b> Per person-month	
<b>Top-up allowance</b>	<b>Special needs allowance</b> (if applicable)	<b>Research, training and networking contribution</b>	<b>Management and indirect contribution</b>
<b>EUR 2 300</b>	<b>Requested unit<sup>1</sup></b> <b>x</b> <b>(1/number of months)</b>	<b>EUR 1 300</b>	<b>EUR 1 000</b>

<sup>1</sup>The pre-defined categories are as follows: EUR 3 000, EUR 4 500, EUR 6 000, EUR 9 500, EUR 13 000, EUR 18 500, EUR 27 500, EUR 35 500, EUR 47 500 and EUR 60 000.

# MSCA COFUND

- **Mono-beneficiary action** to **co-fund** new or existing national, regional, institutional schemes for **doctoral** training and **postdoctoral** fellowships

- **Focus**


- Spread **best practices** of the MSCA by promoting **high standards** in the **recruitment** process and **excellent working conditions**
- Introduce **sustainable structuring effects**, by promoting excellent and sustainable research training
- Encourage **synergies** with Cohesion policy funds as well as the Recovery and Resilience Facility. Bottom-up, but programmes could focus on specific **disciplines**, notably when based on RIS<sup>3</sup>.

- **Target groups**

- **Doctoral candidates**, i.e. researchers without a doctoral degree at the deadline of the co-funded programme's call; mandatory enrolment in a doctoral programme
- **Postdoctoral researchers**, i.e. researchers with a doctoral degree at the deadline of the co-funded programme's call
- Each application can only cover one of the two types of programmes (doctoral/postdoctoral).
- **Researchers apply to vacancies published** by the beneficiary or other partners

- **Who applies?**

- **Single legal entity** established in an EU Member State or HE Associated country
- A minimum of three researchers must be recruited.





# MSCA COFUND

- **Career Development Plan**
  - To be jointly established by the supervisor and each recruited researcher upon recruitment. Revised (and updated where needed) within 18 months
- **Co-funding**
  - Max **10 M€** per beneficiary per call (unchanged)
  - The EU contribution covers **minimum remuneration** and can be used more **flexibly**
- **Duration**
  - **Programme:** max. 60 months (unchanged)
  - **Fellowship:** min 3 months
  - **Secondments:** up to 1/3 of the fellowship duration
- Introduction of an MSCA Cofund **Seal of Excellence** for applications scoring  $\geq 85\%$
- **Call:**
  - **2023:** 10 oct 2023 – 8 Feb 2024; 95,67 M€

# MSCA COFUND – Unit contributions

## Contributions for recruited researchers and institutional contributions

Per person-month

	<b>COFUND allowance</b>	<b>Long-term leave allowance</b> (if applicable)	<b>Special needs allowance</b> (if applicable)
<b>Doctoral Programmes</b>	EUR 2 800	EUR 2 800 x % covered by the beneficiary	Requested unit <sup>1</sup> x (1/number of months)
<b>Postdoctoral Programmes</b>	EUR 3 980	EUR 3 980 x % covered by the beneficiary	Requested unit <sup>1</sup> x (1/number of months)

<sup>1</sup>The pre-defined categories are as follows: EUR 3 000, EUR 4 500, EUR 6 000, EUR 9 500, EUR 13 000, EUR 18 500, EUR 27 500, EUR 35 500, EUR 47 500 and EUR 60 000.

Minimum remuneration applies:

**EUR 2 800 for Doctoral researcher, EUR 3 980 for Postdoctoral researcher**



# Participation of individual researchers

Individuals from third countries can participate in all MSCA actions

<b>MSCA Action</b>	<b>Where to look for vacancies</b>	<b>Where to apply</b>
Doctoral Networks	EURAXESS	Hosting/recruiting institution (or as announced in vacancy)
Postdoctoral Fellowships	Find host organisation/ EURAXESS	FTOP*
Staff Exchanges	Sending institution	Internally
COFUND	EURAXESS	Hosting/recruiting institution (or as announced in vacancy)

\* [FTOP](#): Funding and tender opportunities portal



COMING SOON

## Erasmus+ y Acciones Marie Skłodowska-Curie – Webinario para organizaciones, estudiantes e investigadores de Latinoamérica y el Caribe

Descubre las oportunidades que Erasmus+ y las Acciones Marie Skłodowska-Curie ofrecen para cooperar en educación, investigación e innovación, así como para estudiantes e investigadores de Latinoamérica

27 November 2023 - 29 November 2023

15:00 (GMT+01:00)

134 members are attending  
this event

Log in

Register now



## Erasmus+ y Acciones Marie Skłodowska-Curie

*Webinarios para organizaciones, estudiantes e investigadores en América Latina y el Caribe*

27, 28 y 29 de noviembre de 2023

### Programa provisional

Todos los webinarios tendrán lugar entre las **15h y las 18h, hora de Bruselas** (hora central europea). Consulte la hora correspondiente a su huso horario local. A continuación se ofrecen los equivalentes de las principales zonas horarias:

- Costa Rica, Nicaragua, Honduras, El Salvador, Guatemala, México (Ciudad de México) (UTC-6): 8-11h
- Perú, Panamá, Colombia, Cuba, Ecuador, México (Cancún) (UTC-5): 9-12h
- Brasil (Amazonas) (UTC-4), Bolivia, Venezuela, República Dominicana, Puerto Rico: 10-13h
- Argentina, Brasil (Brasilia) (UCT-3), Chile, Paraguay, Uruguay: 11-14h

<https://research-innovation-community.ec.europa.eu/events/iWoPLr0l3z99eSgxGaRCu/overview>



# Seal of Excellence for MSCA

- Seal of Excellence: quality label awarded to project **proposals** that were judged to **deserve funding** (score over 85%) **but did not get it due to budget limits.**

- Awarded for IF under H2020. Awarded for **PF and COFUND** under Horizon Europe.
- It recognises the value of the proposal and helps **other funding bodies take advantage of the Horizon Europe evaluation process.** It increases attractiveness of hosting countries/regions/inst.

- So far, **14 European countries support Seal of Excellence**-labelled applicants using European, national, regional or institutional **funds** (+other countries considering SoE schemes). 22 schemes:

**ESIF** → CY (ERDF), CZ (ERDF), FR ((Pays de la Loire, ERDF), LT (ESF)

**RRF** → **ES (ISCIII)**, IT, LT (starting 2023), RO, SI (soon), SK (soon)

National funding → AT, BG, PL, SE, SK, SI

Regional funding → BE-Flanders, IT-Bolzano, Lombardy)

Institutional funding → IT (Universities, foundations, research institutions)

*DE Hessen regional scheme expected to resume this year*

*CH scheme may resume if an association agreement to HE is concluded*

*+other countries considering SoE schemes!*

- MSCA Seal covered by EU 2021/1237-GBER (art. 25b): exempted from notification requirement.

[https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/seal-excellence/funding-opportunities-under-msca\\_en](https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/seal-excellence/funding-opportunities-under-msca_en)

# MSCA and Citizens

- **Coordination and Support Action** to bring research and researchers closer to the public at large, through the organisation of the **European Researchers' Night** (+400 cities across Europe, +1,5M visitors) and **Researchers at Schools**
- **Target group:** general public, pupils, students, families and those without easy access and less inclined to research activities
- **Impact**
  - Enhance **engagement with citizens** on R&I
  - Increase awareness among general public of the **importance and benefits of R&I** and its concrete impact on citizens' daily life
  - Contribute to the **diffusion and the promotion of excellence research projects** across Europe and beyond
  - Raise **young people's interest for research** and science
  - Contribute to a better understanding of the EU policies and programmes among the general public;
  - **Support school teachers and educators** in developing a scientific approach around priority topics and creating a learning opportunity for pupils
  - Outcome: improve **researchers' communication skills** and competences
- Proposals should cover the organisation of the **European Researchers' Night** and the implementation of **Researchers at Schools**
- **Who applies?**
  - **One or more legal entities** established in an EU Member State or HE Associated country

# MSCA and Citizens

- **EU contribution**

- **Lump Sum contributions**

- Contribution estimated between **100-300k€ per annual edition** of the European Researchers' Night

- **Duration**

- The call 2023 covers two successive editions (2024-2025)
  - Applicants are encouraged to submit proposals covering **activities for both 2024 and 2025**, including the organisation of two successive editions (2024 and 2025) of the European Researchers' Night and implementation of **Researchers at Schools** activities during the project duration.

- **Call**

- **2023:** 20 Jun 2023 – 25 Oct 2023; 15.42 M€

## 2023 European Researchers' Night

The European Researchers' Night is a Europe-wide public event, which displays the diversity of science and its impact on citizens' daily lives in fun, inspiring ways.

 29 September 2023  Europe-wide

The European Researchers' Night is a Europe-wide public event, which displays the diversity of science and its impact on citizens' daily lives in fun, inspiring ways.

This year, the event will take place in **26 countries** on **Friday 29 September 2023**.

The European Researchers' Night aims to

- bring research and researchers closer to the public
- promote excellent research projects across Europe and beyond
- increase the interest of young people in science and research careers
- showcase the impact of researchers' work on people's daily lives

The European Researchers' Night attracts each year more than 1.5 million visitors in Europe and beyond.





# MSCA Support and other activities

- **MSCA Support (Coordination and Support Actions - Calls for Proposals)**
  - MSCA Feedback To Policy 2023
  - Trans-national cooperation among MSCA NCPs 2024
  - **MSCA International Cooperation 2024**
  - MSCA for Researchers at Risk 2024
- **Other actions not subject to Calls for Proposals**
  - MSCA Presidency conferences (ES 2023, BE 2024)
  - Support to the Marie Curie Alumni Association
  - Special needs allowances to Horizon 2020 legacy projects
  - Public Procurement for Events and Outreach
  - External Expertise

Year	Action	Opening	Deadline
2023	Doctoral Networks	30 May 2023	28 November 2023
	Postdoctoral Fellowships	12 April 2023	13 September 2023
	Staff Exchanges	5 October 2023	28 February 2024
	COFUND	10 October 2023	8 February 2024

*The four actions will have calls in 2024 and 2025.*

*Some dates for 2024 and 2025 will be confirmed in next Work Programme update*

 National Contact Points for Horizon Europe

The network of National Contact Points (NCPs) is the main structure to provide guidance, practical information and assistance on all aspects of participation in Horizon Europe. NCPs are also established in many non-EU and non-associate

Search by

Country Group:

Select a group...

- Member states
- Associated countries
- Countries in process to association
- Third countries

Country(ies):

Select a country...

Function(s):

Choose function(s)

Contact

Contact

Recent


Organisation

### NCP Services

In general, the following basic services are available in accordance with the [NCP Guiding Principles](#) agreed by all countries:

1. Guidance on choosing relevant Horizon Europe topics and types of action
2. Advice on administrative procedures and contractual issues
3. Training and assistance on proposal writing
4. Distribution of documentation (forms, guidelines, manuals etc.)
5. Assistance in partner search

As the NCPs are national structures, the type and level of services offered may differ from country to country.



## MSCA Presidency conference: MSCA diverse research careers to tackle global challenges

The European Commission and the Spanish Presidency of the Council of the EU are organising the upcoming MSCA Presidency conference, which will take place in Toledo, Spain, on 14-15 November 2023.

14 - 15 November 2023 Toledo, Spain

Register now

The European Commission and the Spanish Presidency of the Council of the EU are organising the upcoming MSCA Presidency conference, which will take place in Toledo, Spain, on 14-15 November 2023.

The conference will gather more than 150 participants, from researchers to policy makers, to reflect on how the MSCA promotes diverse research careers to tackle global challenges.

Specific sessions include discussions on

- the contribution of science to policymaking
- the role of the MSCA programme and its impact on the definition of national, regional and local policies to face global challenges
- MSCA's capacity to promote inclusion and diversity in science

Participants will also have the opportunity to discuss the main features of the MSCA programme, in view of the next work programme.



### About the event

The event will gather more than 150 people, attracting the most relevant stakeholders and policymakers to reflect on "MSCA Diverse Research Careers to tackle Global Challenges." It will be structured around the following concepts:



The contribution of science to policymaking, identifying, in addition to the MSCA opportunities, initiatives that are being developed at the regional/national level to support interfaces between science and policy, as well as evidence-based decision-making.



The role of MSCA as a programme with a global dimension that impacts at local, regional and national level, facilitating the definition of policies and initiatives aimed at facing global challenges.



The need to design the best policies based on diversity and integration. The capacity of the MSCA program to promote inclusion and its mechanisms to adapt to emerging challenges will be explored.



The advances of the ERA Policy Agenda in the field of diversification of the research career and intersectoral mobility, which includes public administration, and its links to the MSCA programme.




**Last but not least...**

# Collaborative proposal



**Part-A**  
Admin Questionnaire  
**ONLINE**



**Part-B**  
Technical/scientific Description  
**WORD TEMPLATE**

# In order to learn... try to participate as an expert/evaluator!

<http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html>

European Commission | Funding & tender opportunities | Single Electronic Data Interchange Area (SEDIA) | English | Register | Login

SEARCH FUNDING & TENDERS | HOW TO PARTICIPATE | PROJECTS & RESULTS | **WORK AS AN EXPERT** | SUPPORT

## Work as an expert

The European Union Institutions appoint external experts to assist in the evaluation of grant applications, projects and tenders, and to provide opinions and advice in specific cases.

**Being an expert for the European Commission**

In particular, experts assist in:

- Evaluation of proposals, prize applications and tenders
- Monitoring of actions, grant agreements, public procurement contracts

In addition, experts provide opinion and advise on:

- Preparation, implementation and evaluation of EU programmes and design of policies.

In order to select experts, the European Union Institutions publish regularly calls for expression of interest (see list below) detailing the selection criteria, the required expertise, the description of the tasks, their duration and the conditions of remuneration.

Interested? Please join the database of external experts!

[Register as expert](#)

As new expert, you will be first requested to create your EU login account and register your profile.

Registered experts can update the profile via the My Expert Area after login.

### News

15 Feb, 2021  
**INEA looking for experts to assess CEF Energy calls**  
The Innovation and Networks Executive Agency (INEA) is looking for experienced experts in energy to assess project proposals submitted under the 2021 Connecting...

24 Mar, 2021  
**Call for expression of interest 2021-2027 – New**  
The new call for expression of interest for experts for the programming period 2021-2027 is now open. Note: if you are already registered as an expert answering...

### Quick Links

- Experts standard briefing slides
- FAQ for Experts
- Expert recommendations
- Lists of contracted experts
- EU Grants - Model Contract for Experts
- Methodology for expert fees for remote evaluation and ethics review
- FAQ on the evaluation of innovation, social sciences and humanities and other aspects of H2020 proposals

### Calls for expressions of interest for experts

- Calls for expressions of interest for experts (2021-2027)
- Calls for expressions of interest for experts (2014-2020)

Looking for many different profiles:  
Scientific-technical, business, entrepreneurs,  
public entities, cluster managers, associations,  
NGOs...

## European Research Executive Agency



### Funding high-quality research and innovation

REA's mission is to help build a greener Europe with prosperous, inclusive societies and economies that take full advantage of the digital age.

## Funding and grants

Horizon Europe: Cluster "Culture, creativity and inclusive society"

Horizon Europe: Cluster "Civil security for society"

Horizon Europe: Cluster "Food, bioeconomy, natural resources, agriculture and environment"

Horizon Europe: Widening participation and spreading excellence

Horizon Europe: Reforming and enhancing the European R&I system

Horizon Europe: Research infrastructures

Horizon Europe: Marie Skłodowska-Curie Actions

Research fund for coal and steel

Promotion of agricultural products

## Working for REA

### About REA

The REA's mandate is to manage several EU programmes and support services.

### Jobs at REA

Vacancies at REA and information on the recruitment process and contract types

### Work as an expert

Opportunities for independent experts in the evaluation of project proposals

## European Research Executive Agency

## Work as an expert

### PAGE CONTENTS

[Call for experts](#)

[Profiles & expertise](#)

[Nature of the assignment](#)

[How to register](#)

[Practical information for contracted experts](#)

### Call for experts


The European Research Executive Agency (REA) invites experts from a wide range of fields to register in the [European Commission's experts database](#). From this database, we select candidates with the most suitable profile for the following activities:

- Evaluating project proposals applying for funding under Horizon Europe, the Promotion of Agricultural Products programme and the Research Fund for Coal and Steel, or
- Monitoring the implementation of funded projects.

### Profiles & expertise

We are in particular looking for experts from the following sectors:

- Industry, business associations and innovation agencies,
- Non-governmental organisations (NGOs) and other civil society organisations,
- Local, regional and national administration,
- International organisations,
- Universities and research institutes.





# Looking for experts/evaluators in...

## Food and agriculture

- Forestry including agroforestry, wildfire prevention, hands-on experience in forest management and ecosystems
- Sustainable agriculture, aquaculture and food systems including plant health, weed and pest management, pesticide reduction, veterinary medicine; climate-smart farms and forests, climate resilience
- Digitalisation in farming including precision agriculture, remote sensing or GIS for sustainable farms, fisheries and food supply chains
- Nutrition including sustainable diets, quality labels for dietary shift
- Communication and marketing of agricultural products including promotional strategies, market research, public relations, advertising

## Environment and bio-economy

- Remote sensing, spatial planning, maritime observation
- Lifecycle assessment and analysis
- Circular economy, food waste, sustainable packaging, value chains
- Biodiversity, ecosystems
- Zero pollution, pollution removal, carbon cycle, water security

## Civil security

- Law enforcement including police, border security, crime and anti-terrorism experts
- Civil protection, fire fighters, medical emergency teams
- Cyber security, sensors, UAVs/drones
- Chemical, biological, radiological and nuclear materials

## Engineering, IT and technologies

- Cloud computing, big data, data interoperability, data mining, data visualisation, digital twins
- Artificial intelligence (AI), machine learning, deep learning
- Robotics
- e-Government, open government
- Bioinformatics
- 3D printing, 3D modelling
- Augmented reality, virtual reality
- Blockchain
- Nanotechnology
- Seismology
- Electric propulsion and electric vehicle batteries



## Culture and creativity

- Cultural heritage: curation, restoration, conservation
- Creative industries, collective memory, cultural tourism
- Archaeology, artefacts, museology

## Democracy and society

- International cooperation including globalisation, diplomacy, global governance, international relations
- Disinformation, misinformation, fake news, press freedom, media studies
- Radicalisation including terrorism, extremism, hate crime, homophobia, fascism, racism, stigmatisation, postcolonial studies
- Migration and integration including Islam, human rights, conflict resolution/management, peacebuilding
- European identity, European studies, political science, political philosophy
- Citizen participation, youth participation
- Democratisation, solidarity, polarisation, elections, populism, corruption
- Social inclusion, labour market, robotisation, social stratification, ageing, lifelong learning, econometrics
- Digital literacy including digital services, digital transformation, digital governance, digital democracy, user-centric services

## Other fields of science and innovation

- Social sciences and humanities including gender studies and ethics
- Open science: open data, open source, interdisciplinary research
- Open innovation, knowledge transfer, commercial take-up
- Physics
- Medicine

# RESEARCH & INNOVATION TRANSFORMING EUROPEAN HEALTHCARE

16 November 2023 | 09:00 – 17:00

Permanent Representation of Slovenia to the EU  
Boulevard du Régent 45-46, 1000 Brussels

The Slovenian Business & Research Association (SBRA), in cooperation with Istanbul IT Valley, the Lithuanian RDI Liaison Office in Brussels (LINO), the NCBR Office in Brussels, Eötvös Loránd University and the National Research, Development, and Innovation Office in Hungary have the pleasure to invite you to **Research & Innovation Transforming European Healthcare** taking place in Brussels, Belgium.

The objectives of the conference are to:

- learn about current EU policies and programmes in healthcare research;
- gain knowledge of different research partnerships, associations, and other organisations (i.e., Swiss funding in research & innovation);
- promote research ideas, activities and achievements to the broader research & innovation audience in Brussels (EU representation offices of different national and regional research, innovation and business organisations);
- provide feedback to the European Commission and other speakers at the event.

## Agenda

09:00	Registration
09:30	<b>Welcome speeches:</b> <ul style="list-style-type: none"> <li>• <i>Iztok Jarc, Ambassador, Permanent Representative of Slovenia to the EU</i></li> <li>• <i>Faruk Kaymakçı, Ambassador, Permanent Representation of Turkey to European Union (TBC)</i></li> <li>• <i>Dr. Levin Pal, Assistant Acting Director, Slovenian Research and Innovation Agency</i></li> <li>• <i>Serdar İbrahimcioğlu, President, IT Valley</i></li> <li>• <i>Dr. Draško Veselinovič, President of the Slovenian Business &amp; Research Association (SBRA)</i></li> </ul>
09:50	<b>Presentation of the EU Health Research</b> <ul style="list-style-type: none"> <li>• <i>Carmen Laplaza Santos, Head of Unit, European Commission, DG Research &amp; Innovation (TBC)</i></li> </ul>

10:10	<b>PART 1: INNOVATIVE HEALTH TECHNOLOGIES</b> Showcasing and sharing ideas for health research ( <b>pitching session</b> ) <ul style="list-style-type: none"> <li>• <i>Up to 10 pitches</i></li> </ul>
11:10	<b>Coffee break</b>
11:30	<b>Part 2: ADVANCED MATERIALS IN HEALTH</b> Showcasing and sharing ideas for health research ( <b>pitching session</b> ) <ul style="list-style-type: none"> <li>• <i>Up to 10 pitches</i></li> </ul>
12:30 – 13:30	<b>Brokerage Sessions &amp; Networking Lunch*</b>
13:30	<b>Presentation of strategic programming of Horizon Europe</b> <ul style="list-style-type: none"> <li>• <i>Dr. Massimiliano Esposito, Head of Unit “Common Strategic Planning &amp; Programming Service”, European Commission, DG Research &amp; Innovation (TBC)</i></li> </ul>
13:50	<b>EU research landscape</b> <ul style="list-style-type: none"> <li>• <i>Sergej Možina, Counsellor for Research, Permanent Representation of Slovenia to the EU</i></li> </ul>
14:10	<b>Implementing health research projects: Evaluation process in Horizon Europe</b> <ul style="list-style-type: none"> <li>• <i>Stéphane Hogan, Head of Unit, HaDEA – Health and Digital Executive Agency (TBC)</i></li> </ul>
14:30	<b>Research partnership on health – Innovative Health Initiative</b> <ul style="list-style-type: none"> <li>• <i>Hugh Loverty, Executive Director, Innovative Health Initiative</i></li> </ul>
14:50	<b>Horizon Europe – EU Cancer Mission</b> <ul style="list-style-type: none"> <li>• <i>Annika Nowak, Head of Sector, Cancer Mission Secretariat, European Commission, DG Research &amp; Innovation</i></li> </ul>
15:10	<b>Vanguard Initiative – Smart Health pilot</b> <ul style="list-style-type: none"> <li>• <i>Melissa Campagno, Coordinator of Vanguard Smart Health Pilot Team</i></li> </ul>
15:30	<b>Swiss programmes for research cooperation</b> <ul style="list-style-type: none"> <li>• <i>Simon Marti, Head of SwissCore Brussels</i></li> </ul>
15:50	<b>Q&amp;A and discussions</b>
17:00	<b>End of conference</b>

\*The Networking Lunch is kindly provided by our partner organisation, the Lithuanian RDI Liaison Office in Brussels (LINO).

[REGISTER HERE](#)

Sponsored by

<https://lino.lmt.lt/wp-content/uploads/2023/10/Research-Innovation-Transforming-European-Healthcare-Programme-v9.10.2023.pdf>





**Many thanks!**






# PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

MSCA Doctoral Networks: award criteria		
Excellence	Impact	Quality and efficiency of the implementation
Quality and pertinence of the project's research and innovation objectives	Contribution to structuring doctoral training of European level and strengthening European innovation capacity	Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort
Soundness of the proposed methodology	Credibility of the measures to enhance the career perspectives of researchers and contribution to their skills development	Quality of the work package assigned to each participant, including housing arrangements and extent to which the consortium as a whole brings together the necessary expertise
Quality and credibility of the training programme	Substantive and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities	
Quality of the supervision	The magnitude and importance of the project's contribution to the expected scientific, societal and economic impacts	
50%	30%	20%

## THANK YOU!

PLEASE USE THE CHAT FOR QUESTIONS, SUGGESTIONS AND/OR COMMENTS.  
WE WILL ANSWER/DISCUSS ALL OF THEM.



# PROTEOCURE

# ProteoCure Cost Action Network Opportunities for Funding and Collaboration



October 30, 2023 10:00 – 12:30 hours

## AGENDA

10.00 h (5')	Welcome	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure Olivier COUX, Chair, ProteoCure Cris RAJO, Grant Holder Manager, ProteoCure
10.05 – 10.50 h (45')	Funding Opportunities for Health Research under Horizon Europe	Marina MARTINEZ, Horizon Europe Programme Officer, CDTI SOST-Brussels, Directorate of European Programmes and Regional Cooperation
10.50 – 11.30 h (40')	<b>Success experiences from participation in EU-projects</b>	<b>Rune MATTHIESEN, WG2 Leader, ProteoCure. Coordinator of EVCA, European Call Twinning 2020</b> <b>Rosa BARRIO, Grant Awarding Coordinator, ProteoCure. Coordinator of COST Proteostasis and UPSTREAM, ITN program</b> <b>Manuel S. RODRIGUEZ, Science communication co-leader, ProteoCure, Coordinator of ubiCODE, Marie Skłodowska-Curie Actions</b> <b>Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project, HORIZON.2.1 - Health</b> <b>Olivier COUX, Chair, ProteoCure</b>
11.30 – 12.20 h (50')	Get your Project Funded! - Working Group for ProteoCure funding proposals	All attendees
12.20 – 12.30 h (10')	Closing Remarks & Future Actions	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure COST Action Olivier COUX, Chair, ProteoCure COST Action

# PRACTICAL ISSUES

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



[Sharing your screen or desktop on Zoom – Zoom Support](#)



## Questions for debate

Please raise a virtual hand to indicate that you wish to contribute or ask a question


# PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 - 12:30 hours

## SUCCESS EXPERIENCES FROM PARTICIPATION IN EU-PROJECTS

Rune **MATTHIESEN**, WG2 Leader, ProteoCure.

Coordinator of EVCA, European Call Twinning 2020



**PROTEOCURE**





# Introduction & Background



## **Rune Matthiesen**

*Computational and Experimental Biology (CEB)*

*NOVA MEDICAL SCHOOL / FACULDADE DE CIÊNCIAS MÉDICAS  
UNIVERSIDADE NOVA DE LISBOA*

*E-mail: [rune.matthiesen@nms.unl.pt](mailto:rune.matthiesen@nms.unl.pt) | [www.nms.unl.pt](http://www.nms.unl.pt)*

## **Experience with European fundings:**

2014-2018: COST Action 'Proteostasis', national representative for Portugal

2021-2025: COST Action 'ProteoCure', national representative and MC

2022-2025: Twining project EVCA, coordinator

External expert / evaluator of various European projects







# Introduction & Background




**LYMPHOMA**



**UROLOGICAL CANCER**



**LUNG CANCER**



**1 Study design**



Healthy patients      Patients with disease

**2 Sample collection**

Blood, urine, pleural effusion




**3 Pre-treatment**

Extraction protocols




**4 Data Acquisition**

Mass Spectrometry




**5 Statistical analysis**

Identification of proteins and protein isoforms




**6 Biomarker identification**



**7 Pathway Analysis**

Further analysis and database searches



**8 Biological interpretation**

Further analysis to validate potential biomarkers



# Funding



**Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles**

***Funded by the European Union (Horizon2020 GA n° 101079264)***

Estimated Project Cost: €1,487,209.13

Duration: 36 months

Rune Matthiesen



UNL

Paulo Pereira



*Graça Raposo*



Institut Curie

*Juan M Falcón-Pérez*



CIC bioGUNE





# Funding process

## Writing process:

1. Direction called for proposal to twinning and teaming calls (widening countries)
2. Checked requirements
3. Extracellular vesicles in clinical applications
4. Involved other researchers and we also hired a company to help with the proposal
5. 4 months of writing
6. Grant agreement (3 months)

## Challenges:

Time

Motivation of advanced partners





# Challenges Faced

## Strategies

1. Inclusiveness
2. Planned meetings and deadlines

## Challenges:

1. To low allocation of HR for advanced partners
2. Institut Curie – researchers are from CNRS and INSERM
3. Short time for hiring project manager
4. Institutional change of direction



# Project Highlights



## Milestones (1 year)

1. Established research projects with advanced partners
2. Mapping state of the art within EV research in UNL
3. Outreach activities
4. Workshops
5. Enabled 12 start up projects



Project manager  
Judite Costa





## Networking

1. Companies
2. ISEV network



# Lessons learned

1. Ensure you are well-prepared for the grant agreement.
2. Keep number of project deliveries reasonable.
3. Look for project manager already when the project is approved.
4. Start planning the first events before project start.
5. Enjoy the ride.





# Future directions



Increase funding from companies



Teaming application



EU applications with advanced partners



Rune Matthiesen



Paulo Pereira



António Jacinto



Michel Kranendonk



José António Belo



Sandra Tenreiro



Cláudia Nunes dos Santos



Cláudia Guimas Almeida



Rita Teodoro



Paula Macedo



Rita Machado de Oliveira



José Cabeçadas  
Medical Doctor



Helena Canhão



Helena Soares



Sofia de Azeredo Pereira



Duarte C. Barral



Judit Morello



**João Ferreira**  
Post Doctoral Researcher



**Ana Carvalho**  
Post-Doctoral researcher



**Rúben Rodrigues**  
Post-Doctoral Researcher



**Judite Costa**  
EVCA Project Manager



**Jorge Santos**  
Project Manager



**Sofia Almeida**  
Post-award office coordinator



**Ana Tavares**  
Head of Research Operations



**Graça Raposo**



**Clotilde Théry**



**Sarah Watson**



**Thierry Dubois**



**Christophe Lamaze**



**Stephanie Descroix**



**Nicolas Manel**



**Claire Wilhelm**



**Joao Miguel Vilhena**  
Training unit – Project Coordinator



**Zeina Chamoun-Morel**  
Training project coordinator



**Vincent Birrien**  
Post-Award Finance Officer





**Juan Manuel Falcón Perez**



**Félix Royo**  
Co-PI



**Ana M Aransay**  
PLATFORM MANAGER  
Genome Analysis Platform



**Félix Elortza**  
PLATFORM MANAGER  
Proteomics Platform



**Itziar Gil de la Pisa**  
PROJECT MANAGER

## Advisory Board



**Guillaume van Niel**  
Center of Psychiatry and  
Neurosciences, France  
(EV research, neurodegeneration)

**Marca M.H.M.**  
Faculty of Veterinary Medicine at  
Utrecht University, The Netherlands

(Intercellular communication in  
biological systems via extracellular  
vesicles with emphasis on immune  
system and oncology regulation.)



**Henrique Girão**  
iCBR-Coimbra Institute for Clinical and  
Biomedical Research, Portugal  
(Proteolysis and Intercellular  
Communication)



**Bruno Costa-Silva**  
Champalimaud Foundation, Portugal  
(EV research in oncology)



**Eva-Maria Albers**  
Johannes Gutenberg  
University, Germany  
(EV research, cell  
communication)



**Cristina Alonso**  
OWL, Spain  
(Company in metabolomics of  
clinical samples)



**Joana Simões Correia**  
Executive Director of Exogenus  
Therapeutics, Portugal  
(Exogenus T. is a biotech  
company developing  
healthcare products based on  
EVs and exosomes)

# PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

## SUCCESS EXPERIENCES FROM PARTICIPATION IN EU-PROJECTS

Rosa **BARRIO**, Grant Awarding Coordinator, ProteoCure.  
Coordinator of COST Proteostasis and UPSTREAM, ITN  
program, co-coordinator UbiCODE



**PROTEOCURE**



# Introduction & Background

## Role of Ubiquitin-likes in Development

SUMO, ubiquitin, *Drosophila* development, rare diseases, development of technology and tools to study the ubiquitin system in cells and *in vivo*

- 2012-2015: 'UPStream' European ITN MSCA, Coordinator (Co-coordinator MS Rodriguez)
- 2014-2018: COST Action 'PROTEOSTASIS', Chair and CIC bioGUNE Grant Holder
- 2018-2022: 'UbiCODE' European ITN MSCA, Co-coordinator (Coordinator MS Rodriguez)
- 2021-2025: COST Action 'ProteoCure', Grant Awarding Coordinator

**UPStream**  
EUROPEAN RESEARCH TRAINING IN  
THE UBIQUITIN PROTEASOME SYSTEM




Ubi  
|  
CODE







# Funding



**PROTEOSTASIS**

## **PROTEOSTASIS COST Action BM1307**

**European network to integrate research on intracellular proteolysis pathways in health and disease (PROTEOSTASIS)**

**25th April 2014 until 24th April 2018**


**<https://cost-proteostasis.eu/>**

1<sup>st</sup> Year 156,000.00 €

2<sup>nd</sup> Year 164,000.00 €


3<sup>rd</sup> Year 151,000.00 €

4<sup>th</sup> Year 160,000.00 €



# Application process

PROTEOSTASIS did not start from zero...



Manuel S. Rodriguez

Smaller

Thematically more restricted

Mainly Spanish and French groups

Proposal writing was a concerted effort



Spain



Rosa Barrio

Spain



Manuel S. Rodriguez

Israel



Michael Glickman

France



Olivier Coux

France




Marc Piechaczyk

France



Dimitris Xirodimas



# Application process


**Preproposal** → **Proposal** → **DC Hearing**

**17 COUNTRIES**  
**73 LABS**  
**Men: 48 = 66% Women: 25 = 33%**



Institution List/per country:  
Teams in University : 22  
Teams in R&D centres : 42  
Teams in Hospitals :6  
Teams in Enterprises (SME): 3  
Total Universities: 20  
Total R&D centres : 29  
Total Hospitals :5  
Total Enterprises (SME): 3

**You need have a lot of contacts to support you!**



# Application process



- **The authors fail to describe the innovative value of their proposal**
- **The problem in this field is that it is very widespread and this COST proposal could bring 17 key players together, 5 SME's.**
- **A list of networking activities is included but no added value of the partner's interaction is clearly exposed.**
- **This proposal is arising from a previous project INPROTEOLYSIS and thus by that it is repetitive and not innovative.**
- **However, the milestones are not clearly presented and justified and they are only included in the time table**





# Challenges Faced in the Application

- **Large number of people need to get coordinated for the proposal:**
  - need to follow up information from many participants for the proposal, send questionnaires, emails, etc. **Get people engaged!**
- **Be ambitious but realistic in the proposal**
  - the Objectives should be objectives for the field, not objectives of your particular project



# Challenges Faced in the Application

## Objectives

### **INTEGRATION**

To defragment the field and increase communication.

### **TRANSLATIONALITY**

To facilitate the transfer from basic to translational science.

### **TECHNOLOGY**

To foster technology and knowledge in protein homeostasis.

### **TRAINING**

To create and consolidate training efforts in the field.



# Challenges Faced in the Application

- **Large number of people need to get coordinated for the proposal:**
  - need to follow up information from many participants for the proposal, send questionnaires, emails, etc. **Get people engaged!**
- **Be ambitious but realistic in the proposal**
  - the Objectives should be objectives for the field, not objectives of your particular project
- **Make clear the differences with previous projects**
  - why your project is necessary?
- **These proposals are a lot of work, you need help**
  - get help from professionals, people with experience, good collaborators



# Challenges Faced in Management

- **COST rules might be complicated**
  - you need to have a Project Manager!!
- **COST budget is decided yearly, difficult to plan ahead**
  - anticipate expenses as much as you can
- **Large number of people need to get coordinated for the network**
  - you need to have a Project Manager!!
  - organization, organization, organization!
- **You need the support of your institution if selected as Grant Holder**
  - many institutions will not accept this challenge
  - large institutions are less flexible
- **Bottom up: let the people suggest the activities in which they are interested**
  - keep people engaged, be flexible, work for the people's best benefit
  - surround yourself with people who want to work, ignore the others





# Challenges Faced in Management



**Emilia Moreira**



**CIC bioGUNE**



**Grant Holder**




**Inga  
Dadeshidze**

**Science  
Officer**



**Andrea  
Tortajada**

**Admin  
Officer**




**Gabriela  
Cristea**

**Admin  
Officer**





# Project Highlights



**PROTEOSTASIS**

## PROTEOSTASIS in numbers



**Participant Groups**

**274**

**Participant Countries**

**27 + Ukraine + USA + Republic of Korea**

**Number STSMs**

**47**



**Number of Meetings**

**14**

**Number of Dissemination & ITC Meetings**

**22**

**Number of Training Schools Organised**

**8**



**Number of videos**

**23**

**Number of open webinars**

**7**

**Number of newsletters**

**6**



**Joint International Publications**

**43**

**H2020 proposals**

**20**

**Other Collaborations**

**14**


**Reimbursed participants 426**

**Dissemination**

**Collaborations**



# Outputs of PROTEOSTASIS



Ubi  
CODE

TrainERS

METACAN  
Metabolism Immunity Cancer

TRIM NET



# Outputs of PROTEOSTASIS



1 non-successful applications

2 non-successful applications

Ubi  
CODE

TrainERS

METACAN  
Metabolism Immunity Cancer

TRIM NET





# Take home message

## For application

- Find an important, innovative goal where having a big consortium can be relevant
- Don't get discouraged; most grants need more than one application
- Seek help from experts (professionals, people with experience, etc)
- Get good travel companions (committed, supportive)

## For management

- You need support from good project manager!
- You need support from Grant Holder institution!
- Surround yourself with people committed to working for the community




# Core group members and organizers







# A unique experience



The Final COST Action BM1307 Meeting  
PROTEOSTASIS COST  
**Proteostatic Mechanisms in Health and Disease**  
February  
Athens





# PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours



**THANK YOU!**

**PLEASE USE THE CHAT FOR QUESTIONS, SUGGESTIONS  
AND/OR COMMENTS.**

**WE WILL ANSWER/DISCUSS ALL OF THEM.**



**PROTEOCURE**



PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR  
FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

# SUCCESS EXPERIENCES FROM PARTICIPATION IN EU-PROJECTS

Manuel S. **RODRIGUEZ**, Science communication co-leader,  
ProteoCure, Coordinator of UbiCODE, Marie Skłodowska-  
Curie Actions



**PROTEOCURE**



# Introduction & Background

HORIZON  
2020

**UbiCODE: European Research Training to Decipher The Ub Code : identification of potential biomarkers and drug targets**

Grant agreement ID: 765445: **Coordinated by** CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

**KEYWORDS:** Ubiquitin, Ubiquitin-like proteins, Ubiquitin- Enzymes, Proteasome

**4 Scientific WP: Writing, Editing, Reading, Interpreting**

**5 Management WP**

- **12 Fellows, 10 Beneficiaries, 9 Associated Partners**
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS ( 2 fellows: ITAV – CRBM)
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
- ACADEMISCH ZIEKENHUIS LEIDEN
- FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH FONDATION
- THE UNIVERSITY OF LIVERPOOL
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCENCIAS
- JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
- INSTITUT FUR MOLEKULARE BIOLOGIE GGMBH
- UNIVERSITY OF DUNDEE (2 Fellows)
- NOVO NORDISK A/S



# First application 2016 call

## Evaluation Summary Report

Total score 84.20% Threshold 70/100

Criterion 1: Excellence: Score: 4.10/5. Weight: 50%

Overall comments: *The consortium proposes an innovative and sound research programme. The training plan is comprehensive and overall appropriate and takes into consideration multi-disciplinary and inter-sectoral aspects. The supervisory team demonstrates highly appropriate experience and a track of scientific excellence.*

*The logistics of several aspects such as training modules, secondments and joint supervision is not sufficiently detailed.*

Criterion 2: Impact: Score: 4.40/5. Weight: 30%

Overall comments: *The research program shows potential to have relevant impact on scientific development and career perspectives of recruited ESRs and to generate an inter-sectoral network of excellence. Overall, proposed dissemination and communication activities are appropriate, although the latter are not detailed in a precise action plan.*

Criterion 3: Quality implementation: Score: 4.20/5. Weight: 20%

Overall comments: *The overall work plan is well delineated. Management structures are highly appropriate and well described. The consortium is cohesive and shows potential for a fruitful collaboration and infrastructures are well suited for the proposed work. The integration of some aspects regarding individual research projects (focus of the research, secondment periods) in the global research programme is in some cases not entirely convincing.*



# Second application 2017 call

## Evaluation Summary Report

**Total score 96.6% Threshold 70/100**

Criterion 1: Excellence: Score: 4.8/5. Weight: 50%

Weaknesses:

- *Although contribution to the potential exploitation of project results is mentioned, the contribution of the non-academic beneficiary and partners to the research program, scientific quality, and innovation is not discussed with sufficient detail.*
- *The consortium offers a set of excellent training modules. However, the choice of making some essential courses optional will prevent ESR training from being comprehensive, and skill sets of individual ESRs will not correspond to standards set for the consortium as a whole.*

Criterion 2: Impact: Score: 4.9/5. Weight: 30%

Weaknesses :

- *Not all ESRs have the opportunity for secondments in a non-academic environment.*

Criterion 3: Quality implementation: Score: 4.8/5. Weight: 20%

Weaknesses :

- *Several training elements, including secondments, are rather short for the stated goals.*
- *Some of the WPs and ESR project deliverables and milestones are not measurable.*





# Funding

€ 3 407 194,44 /12 beneficiaries


240k € – 290 k €

Covered: Salary and Training expenses

Started in 2018 - 2023

## **Lessons learnt: From first application in 2016 to second application in 2017**

- Equal opportunities to fellows
- Participation of private sector highly important: important for secondments in private sector
- Detailed description training, secondments, supervision: Important challenge to do in a reduced space
- Integration and interactions between WP
- Deliverables and milestones should be measurable
- Communication plan better explained
- Global research program better described ; well integrated, better justified and coherent



# Funding and application process

- First application with the help of CNRS European project manager
- Second application we have in addition a consulting service specialized in Marie Curie grants

## Lessons to retain

- Select a co-coordination partner to better complete the application : **ROSA BARRIO**
- One year in advance, select your partners in coherence with a global program: Individual proposals should be innovative and interesting BUT they have to fit well together.
- ITNs/DNs are integrated projects: as individual projects have to be interconnected BUT independent. The failure of one project cannot condition the development of the other projects.
- The focus of the ITNs/DNs is TRAINING! It is not a scientific project (although it uses an innovative project for the purpose of the training): Everything has to be done BY the Fellows (Doctoral Candidates) and FOR the Fellows.
- Apply for funding to obtain consulting support (when possible)
- Equal opportunities at all levels including gender balance
- Select beneficiaries that are pro-active, good responders and willing to contribute to the program


## PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

### SUCCESS EXPERIENCES FROM PARTICIPATION IN EU-PROJECTS

Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project,  
HORIZON.2.1 - Health

[izoidakis@biol.uoa.gr](mailto:izoidakis@biol.uoa.gr)





# Introduction & Background

**Studied Biochemistry at the University of Liege and did my PhD at UCLA on enzyme catalysis and biophysical characterisation. Recipient of a MSCA-IF.**

**My research focuses on mass spectrometry-based proteomics analysis**

**Double affiliation: University of Athens, Biology Department**

**Biomedical Research Foundation, Academy of Athens, Biotechnology Department**






# Funding

Since 2009 I have participated to several types of EU funded projects  
COST, MSCA-ITN/DN, RIA, Twinning  
Also in a few national projects

## Lessons learnt

- Scientific research is full of surprises (pleasant and unpleasant)
- Grant administration, particularly the ethics and financial part, is full of only unpleasant surprises
- Keep calm and discuss in order to resolve conflicts



# Funding process: Requirements for interdisciplinary and intersectoral collaborations

- Successful interdisciplinary consortia include:
  1. Researchers in life sciences disciplines (biologists, biochemists, etc.)
  2. Clinicians
  3. Epidemiologists
  4. Computer scientists with expertise in statistics, data management, bioinformatics and AI
  5. Engineers (wearables, cell phone applications)
- Successful intersectoral consortia include:
  1. Academic institutions
  2. Industrial partners (preferably Small and Medium Enterprises-SME)
  3. International agencies (International Agency for Research on Cancer-IARC, European Medicines Agency-EMA)
  4. Non-Governmental Organisations-NGO (patient organisations)
  5. **Company with expertise in grant management and dissemination activities**



## Funding: How do I find partners?

- Look into your network of collaborators (easiest and safest option)
- Cooperation of Science and Technology COST actions
- National and International meetings
- EU funding calls portal (post expertise and ask to be included in consortia of specific calls)
- Sign up for online networking/brokerage events organized by the EU
- Use the networking services of scientific societies (European Association for Cancer Research-EARC, Federation of European Biochemical Societies-FEBS)
- Refer to national contact points for EU grants
- Contact authors who have published exciting results (M. Mishto, peptide splicing)

*ProteoCure Cost Action Network Opportunities for Funding and Collaboration*  
October 30, 2023 10:00 – 12:30 hours





# Positive examples of consortium building: Network of Collaborators

Meletios-Athanasios Dimopoulos, Rector University of Athens

<https://www.scopus.com/authid/detail.uri?authorId=55978800700> h-index 128

Leader in translational research and clinical trials for Multiple Myeloma (MM)


1. Greek National Research Grant (MyBioTag, 2018-2023) for new therapeutic target discovery by proteomics and transcriptomics (4 partners, 1 million Euros total budget)
2. ELMUMY (Elucidation of Risk Factors and Health Determinants Associated with Progression of Monoclonal Gammopathies to Multiple Myeloma, HORIZON Jan 2023- Dec 2026, 10 million Euros total budget for 14 partners)  
<https://www.elmumy.eu/>





# ELMUMY objectives and work plan


- Develop a systematic understanding of cellular processes with a focus on the transition from a healthy state to cancer initiation and progression, at the individual or population level
- Define early interventions that prevent disease progression in functional preclinical models





# Challenges Faced: mainly associated with primate behaviour patterns

Bonobos have matriarchal social structures and rely on sharing power and resources



Chimpanzee groups are led by a dominant alpha male with aggressive behavior that monopolizes power and resources





VALENCIA BIOMEDICAL  
RESEARCH FOUNDATION  
CENTRO DE INVESTACION PRINCEPI VLLIB



Funded by  
the European Union

## CONCLUDING REMARKS

EU OFFERS A LOT OF COLLABORATIVE OPPORTUNITIES AND REQUIRES FORMATION OF CONSORTIA WITH INTERDISCIPLINARY AND INTERSECTORAL CHARACTERISTICS

SCIENTISTS WITH PLEASANT PERSONALITIES FORM SUCCESSFUL CONSORTIA THAT RELY ON SHARING POWER AND RESOURCES

COST ACTIONS, PERSONAL NETWORKS AND SCIENTIFIC MEETINGS ARE PREFERRED OPTIONS FOR JOINING AND CREATING CONSORTIA

**FAIL, FAIL BETTER, EVENTUALLY SUCCEED**

**THANK YOU!**

**PLEASE USE THE CHAT FOR QUESTIONS, SUGGESTIONS AND/OR COMMENTS.**

**WE WILL ANSWER/DISCUSS ALL OF THEM.**





VALENCIA BIOMEDICAL  
RESEARCH FOUNDATION  
CENTRO DE INVESTIGACION PRINCIPE FELIPE



Funded by  
the European Union

PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR  
FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

# PARTICIPATION IN EU-PROJECTS: WHAT PROTEOCURE CAN DO FOR YOU

Olivier COUX, Chair, ProteoCure



**PROTEOCURE**



European  
Commission





# Background

**Scientific background: Proteasome and its regulators, UbLs (SUMO)**


**Experience with European fundings:**

- 2001-2004: FP5 project (7 teams, including 1 startup), **coordinator**
- 2012-2015: 'UPStream' European ITN (Initial Training Network) Marie Curie Network, **partner**
- 2014-2018: COST Action 'Proteostasis', **vice chair, French representative to the MC**
- 2021-2025: COST Action 'ProteoCure', **chair**
  
- External expert / evaluator of various European projects



# What I have learnt

- No self-censoring
  - We all do respectable research, even if we don't have all the same resources or the same visibility
  - “Big” labs are usually happy to join; however do not expect too much help from them
  - Make sure you can deliver (management 😞), deliverables)
- Read the call and the rules carefully
  - Stick to them as closely as possible; being out of line = waste of time
  - Age, gender, geographic, economical and societal issues have to be addressed clearly in all European fundings
- Write in a clear and simple manner (time and competence of the reviewers)
- Participate to evaluations of European projects +++
- Do not improvise (when possible 😊): better to wait for the next call if not ready



# How ProteoCure can help

- In seeking collaborators
  - > 300 ProteoCure members, covering pretty much all areas in biology, and open for collaborations
  - Several members with expertise in chemical and structural biology, biophysics, proteomics, social sciences
  - Some members can offer access to technical / screening facilities

➤ Use ProteoCure website, email lists, meetings
- In building a community on your favorite topic
  - Subgroups within WG1
  - ProteoCure Forum to share information, technical tips, publications
  - Organization of meetings (all sizes), training schools
- In preparing applications
  - Online or face-to-face meetings to discuss the proposal
  - STSMs to produce supporting preliminary data, proofs of concept...
  - Advices (?): discuss with more experienced people (this meeting), invite them to preparation meetings, to comment on the draft application, etc..

# ProteoCure Cost Action Network Opportunities for Funding and Collaboration

October 30, 2023 10:00 – 12:30 hours



## AGENDA

10.00 h (5')	Welcome	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure Olivier COUX, Chair, ProteoCure Cris RAJO, Grant Holder Manager, ProteoCure
10.05 – 10.50 h (45')	Funding Opportunities for Health Research under Horizon Europe	Marina MARTINEZ, Horizon Europe Programme Officer, CDTI SOST-Brussels, Directorate of European Programmes and Regional Cooperation
10.50 – 11.30 h (40')	Success experiences from participation in EU-projects	Rune MATTHIESEN, WG2 Leader, ProteoCure. Coordinator of EVCA, European Call Twinning 2020 Rosa BARRIO, Grant Awarding Coordinator, ProteoCure. Coordinator of COST Proteostasis and UPSTREAM, ITN program Manuel S. RODRIGUEZ, Science communication co-leader, ProteoCure, Coordinator of ubiCODE, Marie Skłodowska-Curie Actions Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project, HORIZON.2.1 - Health Olivier COUX, Chair, ProteoCure
<b>11.30 – 12.20 h (50')</b>	<b>Get your Project Funded! - Working Group for ProteoCure funding proposals</b>	<b>All attendees</b>
12.20 – 12.30 h (10')	Closing Remarks & Future Actions	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure COST Action Olivier COUX, Chair, ProteoCure COST Action




# PRACTICAL ISSUES

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



mircophone  
Unmuted



click to Mute

mircophone  
Muted



click to Unmute



## Qüestions for debate

Please raise a virtual hand to indicate that you wish to contribute or ask a question



# Questionnaire



124 Answers



The purpose of the questionnaire is to gather information about your background, interests, and specific topics you'd like to see addressed during the workshop.





# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## What role does interdisciplinary research play in European funding programs, and how can researchers foster interdisciplinary collaboration in their proposals?

Interdisciplinary research is **highly valued** in European funding programs as it promotes **innovative solutions to complex societal challenges**.

Researchers can foster interdisciplinary collaboration by actively **seeking partners from diverse fields**, leveraging their expertise to address **multifaceted issues**, and emphasizing the **added value** of this interdisciplinary approach in their proposals.


Interdisciplinarity is key in European Projects. **Strong partnerships increase the competitiveness of proposals** and demonstrate the capacity for effective collaboration.

**A COST Action** is an interdisciplinary research network that brings researchers and innovators together to investigate a topic of their choice for four years.


**Fostering interdisciplinary research for breakthrough science is one of COST's strategic objectives.**



What is your main research field/main interest? Please select all that apply



If you replied 'Other' to the question above, please specify any additional main research field/main interest:








# With which areas of research and innovation within the field of Health do you believe you could collaborate?

(please select the ones that align best with your expertise and interests for potential European projects)

- Clinical Research and Trials: Invo... 33
- Public Health and Epidemiology... 5
- Healthcare Technology and Med... 0
- Bioinformatics and Genomic Me... 17
- Biomedical Research and Biotec... 92
- Healthcare Access and Equity: In... 1
- Healthcare Management and Po... 0
- Infectious Diseases and Vaccine ... 24
- Mental Health and Well-being: ... 6
- Aging and Gerontology: Focusin... 34
- Precision Medicine and Personal... 36
- Nutrition and Dietetics: Focusin... 12
- Education Innovation and Skill ... 6
- Global Health and Humanitarian... 7
- Other and/or comments (please... 14



If you replied 'Other' to the question above, please specify any additional areas of research and innovation that you believe are aligned with your research projects and/or research interests:

Drug discovery medicinal chemistry drug development organic chemistry drug delivery chemical biology basis of diseases target validation  
 diseases- Nanoparticle diseases biology drug research  
 glycoprocessing enzymes Cancer biology inhibitor libraries development Cell biology Macrophage interactions  
 atherosclerosis and NAFLD



# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

**What are the key competencies and skills that researchers should develop to excel in European funding applications?**

Researchers should develop **strong proposal writing skills**, as **clear and well-structured proposals are crucial**.

Additionally, **skills in project management, collaboration, and communication** are essential for building a compelling case.

**Being able to align the project with the specific goals of the funding call and demonstrating societal impact are also vital.**

COST mission is: 'to provide **networking opportunities for researchers and innovators in order to strengthen Europe's capacity to address scientific, technological and societal challenges**'.



Are you open to collaborating with ProteoCure Members in the preparation of funding proposals?




87%  
Yes

12%  
No



# On a scale of 1-5, what motivates you to participate in European projects? (1 being least motivating, and 5 being most motivating)







# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## How can researchers engage with industry NGOs and other stakeholders to strengthen the impact and relevance of their research proposals for European funding?

Researchers can engage with industry and stakeholders by establishing **partnerships and collaborations**.

They should actively communicate with **potential partners** to understand their needs and challenges. Demonstrating how the research can practical solutions is key.

Additionally, **involving end-users and stakeholders in the project design and planning process can enhance its relevance and impact**.

**COST Actions are highly interdisciplinary and open.**


**They are multi-stakeholder, often involving the private sector, policymakers as well as civil society.**

# PROTEOCURE CONNECTIONS

ProteoCure Cost Action Network Opportunities for  
Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



ProteoCure aims to promote integration of Academic, Clinics and Industry sectors in order to create a fertile environment for rapid translation of discoveries and ideas into innovative therapies



Kantify, <https://www.kantify.com>

Artificial Intelligence to discover breakthrough therapies

Celeris Therapeutics, <https://celeristx.com>

design novel proximity-inducing compounds (PICs™), to treat diseases with high unmet medical need

PhoreMost, <https://www.phoremmost.com>

next-generation phenotypic screening platform which can discern the best new targets for future therapies and how to drug them.

Biogenity, <https://biogenity.com>

provides a wide range of services for your omics research study.

Domiconus, <https://www.domiconus.com>

providing rare marine cones venoms venoms for research laboratories.

Genepep, <https://www.genepep.com>

provide Peptides and Proteins for therapeutic, diagnostic and cosmetic applications

GlaxoSmithKline

(GSK), <https://www.gsk.com/en-gb/>  
global biopharma company

Novartis,

<https://www.novartis.com>  
global healthcare company

AXIOS senolytics,

<https://axios-senolytics.com>  
natural Nutritional Supplements to improve your Health and your Well-Being

UbiQ, <https://ubiqbio.com>

Ubiquitin research tools



# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## How can researchers effectively communicate the scientific excellence and novelty of their proposed research to reviewers in European funding competitions?

Researchers can effectively communicate scientific excellence by providing a clear and concise summary of their **research's unique contributions**.

Highlighting the **novel aspects**, such as **innovative methodologies** or the **potential to advance the field**, is important.

Providing a **compelling narrative** and using evidence to support claims **can help reviewers** understand the project's significance.

**COST** is committed to bringing out **excellence and inclusiveness** in science Europe-wide and clearing away obstacles for collaboration

# Key principles



Your proposed work must be within the scope of a work programme topic



You need to demonstrate that your idea is ambitious and goes beyond the state of the art



Your scientific methodology must take into account interdisciplinary, gender dimension and open science practices. It must not significantly harm the environment



You should show how your project could contribute to the outcomes and impacts described in the work programme (the pathway to impact)



You should describe the planned measures to maximise the impact of your project ('plan for the dissemination and exploitation including communication activities')



You should demonstrate the quality of your work plan, resources and participants



# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## Can you share personal experiences or anecdotes about overcoming challenges and obstacles in the process of securing European research funding?

One of the answers to the questionnaire includes the following:

*I faced challenges in my first application, including a lack of clear alignment with the funding program's objectives. I learned to carefully read the call guidelines, seek feedback, and revise my proposal accordingly. Collaboration with experienced colleagues and building a strong consortium also helped me overcome obstacles*

**Networking** is an excellent way for individuals at every stage of their career to discover exciting opportunities, meet new connections, and broaden personal research horizons. **COST Actions** have been designed to maximise networking possibilities, featuring a wide range of tools and additional activities, which benefit individuals and wider research networks alike through strengthening research outcomes and community knowledge.





Are you likely to apply for Horizon Europe funding in the future?

62%  
Yes



33%

I am not sure / I do not  
know

4%  
No



# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## How can a consortium ensure their project proposals align with the priorities and objectives of European funding programs?

Consortiums can ensure alignment **by thoroughly understanding the funding program's guidelines, conducting a needs assessment, and collectively defining the project's objectives to match the program's priorities.**


**Regular communication** and feedback among consortium members are essential for maintaining alignment throughout the project.

**To maximize success, it's crucial to start early, thoroughly understand the call requirements, build a strong consortium, develop a compelling narrative, emphasize societal impact, engage with potential end-users, and seek expert feedback through the proposal writing process. Clear communication and adherence to deadlines are also key.**

**COST Actions** help connect research initiatives across Europe and enable scientists to **grow their ideas by sharing them with their peers.**




# How do you consider your current funding status?





# On a scale of 1-5, what motivates you to participate in European projects? (1 being least motivating, and 5 being most motivating)





# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## How can early-career researchers best position themselves to compete for European research grants and projects?

Early-career researchers can position themselves by seeking **mentorship and collaboration with senior researchers, actively participating in relevant research networks, and building a strong research portfolio.**

They should also engage in **continuous skill development and seek opportunities** to lead or contribute to research projects.


### **Proteocure looks forward effective involvement of young researchers:**

- Values of networking within an international and multi-cultural community which has common research interests;
- Going beyond the borders and disciplinary silos;
- Collaborating with young and senior researchers.





If you have previously participated in any European projects, what was your role in the project(s)? (Please do not consider ProteoCure)





# Questions for debate

ProteoCure Cost Action Network Opportunities  
for Funding and Collaboration  
October 30, 2023 10:00 – 12:30 hours



Please raise a virtual hand to indicate that you wish to contribute or ask a question

## What are the most common mistakes researchers make in their European funding applications, and how can these be avoided?

### Common mistakes include:

insufficient **alignment with program priorities**,  
unclear **project objectives**, and  
lack of a **compelling narrative**.

To avoid these, researchers should carefully read the call guidelines, seek feedback, and plan their proposals thoroughly in a collaborative manner.

We can take advantage of **ProteoCure** international collaboration and our diverse expertise and perspectives.

Benefits include access to a wider pool of knowledge, increased visibility, and the potential for larger and more impactful projects.



# Interest and/or potential fit in forthcoming calls

Destination 3: Tackling diseases and reducing disease burden - Horizon Europe


Call 2024: Partnerships in Health

- Overall indicative budget: 100M€
- Indicative number of projects expected to be funded: 1
- Opening: 25 Apr 2024
- Deadline(s): 25 Sept 2024

Topics:  
 HORIZON-HLTH-2024-DISEASE-09-01: European Partnership: One Health Anti-Microbial Resistance (COFUND)



- My research may fit this topic and I would be interested in participating in a proposal for this call (36)
- I would be interested in coordinating/leading a proposal for this call (4)
- My research does not fit this topic (60)




Destination 3: Tackling diseases and reducing disease burden - Horizon Europe


Call 2024: Tackling diseases (Single Stage)

- Overall indicative budget: 52M€
- Indicative number of projects expected to be funded: 6
- Opening: 26 Oct 2023
- Deadline(s): 11 Apr 2024

Topics:  
 • HORIZON-HLTH-2024-DISEASE-08-12: Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness (CSA)  
 • HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential (RIA)



- My research may fit this topic and I would be interested in participating in a proposal for this call (35)
- I would be interested in coordinating/leading a proposal for this call (5)
- My research does not fit this topic (60)



# Interest and/or potential fit in forthcoming calls

**Destination 5: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**  
**Call 2024: Tools and technologies for a healthy society (Single stage)**

- Overall indicative budget: 25 M€ • Indicative number of projects expected to be funded: 4
- Opening: 26 Oct 2023 • Deadline(s): 11 Apr 2024

**Topics:**

- HORIZON-HLTH-2024-TOOL-11-02: Bio-printing of living cells for regenerative medicine (RIA)



- My research may fit this topic and I would be interested in participating in a proposal for this call (23)
- I would be interested in coordinating/leading a proposal for this call (6)
- My research does not fit this topic (95)

77%  
My research does not fit this topic

17%  
My research may fit this topic and I would be interested in participating in a proposal for this call

4%  
I would be interested in...

**Destination 6. Maintaining an innovative, sustainable and globally competitive health industry**

**Call 2024: A competitive health-related industry (Single stage)**

- Overall indicative budget: 12 M€ • Indicative number of projects expected to be funded: 2
- Opening: 26 Oct 2023 • Deadline(s): 11 Apr 2024

**Topics:**

- HORIZON-HLTH-2024-IND-06-08: Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs) (RIA)
- HORIZON-HLTH-2024-IND-06-09: Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training & experience exchange for regulators (CSA)



- My research may fit this topic and I would be interested in participating in a proposal for this call (10)
- I would be interested in coordinating/leading a proposal for this call (4)
- My research does not fit this topic (110)

88%  
My research does not fit this topic


8%  
My research may fit this topic and I would be interested in participating in a..

3%  
I would be..


# Interest and/or potential fit in forthcoming calls

## ERC

- ERC Starting (2-7 years of experience since completion of PhD, a scientific track record showing great promise and an excellent research proposal)
- ERC Consolidator (7-12 years of experience since completion of PhD, a scientific track record showing great promise and an excellent research proposal)
- ERC Advanced (researchers who have a track-record of significant research achievements in the last 10 years. The applicants (Principal Investigators or PI's) should be exceptional leaders in terms of originality and significance of their research contributions)
- ERC Synergy (For groups of two to maximum four PIs working together and bringing different skills and resources to tackle ambitious research problems. PIs must present an early achievement track-record or a ten-year track-record, whichever is most appropriate.)
- ERC Proof of Concept (Only PI's in one of the ERC frontier research main grants (Starting, Consolidator, Advanced or Synergy) are eligible to participate and apply for an ERC Proof of Concept Grant).



- I am planning to apply next call (16)
- I may be applying in the future (58)
- I am not planning to apply (50)
- I am an ERC Grantee (1)





# ProteoCure Cost Action Network Opportunities for Funding and Collaboration

October 30, 2023 10:00 – 12:30 hours



## AGENDA

10.00 h (5')	Welcome	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure Olivier COUX, Chair, ProteoCure Cris RAJO, Grant Holder Manager, ProteoCure
10.05 – 10.50 h (45')	Funding Opportunities for Health Research under Horizon Europe	Marina MARTINEZ, Horizon Europe Programme Officer, CDTI SOST-Brussels, Directorate of European Programmes and Regional Cooperation
10.50 – 11.30 h (40')	Success experiences from participation in EU-projects	Rune MATTHIESEN, WG2 Leader, ProteoCure. Coordinator of EVCA, European Call Twinning 2020 Rosa BARRIO, Grant Awarding Coordinator, ProteoCure. Coordinator of COST Proteostasis and UPSTREAM, ITN program Manuel S. RODRIGUEZ, Science communication co-leader, ProteoCure, Coordinator of ubiCODE, Marie Skłodowska-Curie Actions Makis ZOIDAKIS, WG1, ProteoCure, Coordinator of ELMUMY project, HORIZON.2.1 - Health Olivier COUX, Chair, ProteoCure
11.30 – 12.20 h (50')	Get your Project Funded! - Working Group for ProteoCure funding proposals	All attendees
12.20 – 12.30 h (10')	Closing Remarks & Future Actions	Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure COST Action Olivier COUX, Chair, ProteoCure COST Action



VALENCIA BIOMEDICAL  
RESEARCH FOUNDATION  
CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE



Funded by  
the European Union

PROTEOCURE COST ACTION NETWORK OPPORTUNITIES FOR  
FUNDING AND COLLABORATION

October 30, 2023 10:00 – 12:30 hours

# CLOSING REMARKS & FUTURE ACTIONS

Rosa FARRÀS, Grant Holder Scientific Representative and Vice-Chair, ProteoCure  
COST Action

Olivier COUX, Chair, ProteoCure COST Action



**PROTEOCURE**



European  
Commission



Participation in a COST Action can significantly enhance **opportunities for collaboration in European funding proposals.**

By actively engaging in a COST Action, researchers can establish meaningful connections, **identify potential collaborators**, and build a **strong consortium.**



This collaborative environment fosters **the development of innovative ideas and joint research initiatives that can align with the priorities of European funding programs.**

Additionally, the insights gained from a COST Action can lead to a **deeper understanding of the European research landscape and the specific needs and challenges in various fields**, which is invaluable when crafting **competitive proposals.**





## How do you see the role of European projects in your research/innovation activities in the future?





Have you received any training or support on how to participate in European projects?

52%

No, I have not received any training or support.

39%

I have received some training and support, although I am interested in further training and support.

7%

Yes, I have received extensive training and support

PROTEOCURE





Have you collaborated with other members of ProteoCure on previous project proposal preparation and/or funded projects?

67%  
No



PROTEOCURE


32%  
Yes



# FIT in Key topics identified in the thematic area of Health for 2025-2027.

Please, from the following identified topics choose in which one/ones would you be interested in participating/leading a proposal for 2024-2025.

- Cancer (prevention, cure, treatment, personalised medicine, vaccine development, targeted therapies, aggressive cancers) **78 (24%)**
- Rare diseases (diagnostics, cure) **41 (12%)**
- Dementia (prevention, treatment) **21 (6%)**
- Cardiovascular diseases (prevention, cure) **19 (5%)**
- Autoimmunity and degenerative diseases (prevention, treatment) **30 (9%)**
- Infectious diseases (prevention, cure, viral control) **29 (9%)**
- Chronic diseases (new remedies) **30 (9%)**
- Development of new diagnostics, vaccines, and therapeutics against neglected diseases
- Alzheimer's disease (cure) **25 (7%)**
- Antimicrobial resistance **15 (4%)**
- Multidisciplinary approach to health research, including AI-assisted medical diagnosis
- My research does not fit any topic **8 (2%)**



# Interest and/or potential fit in forthcoming calls


## MSCA Staff Exchanges 2024

MSCA Staff Exchanges provide funding for international, inter-sectoral and interdisciplinary staff mobility and collaborative projects.

- Call opens: 10 October 2024 • Deadline: 5 March 2025
- Budget: 81,23 M€



- I am planning to apply (this call) (10)
- I would be interested in participating, but in future calls (73)
- I am not planning to apply or I am not interested (41)




## MSCA COFUND 2024

The aim of the COFUND action is to spread the best practices of the MSCA, including international, inter-sectoral and interdisciplinary research training, as well as international and cross-sectoral mobility of researchers at all stages of their career.

- Call opens: 8 October 2024 • Deadline: 6 February 2025
- Budget: 99,28 M€



- I am planning to apply (this call) (10)
- I would be interested in participating, but in future calls (60)
- I am not planning to apply or I am not interested (54)



# Interest and/or potential fit in forthcoming calls

## MSCA Doctoral Networks 2024

MSCA Doctoral Networks will implement doctoral programmes, by partnerships of universities, research institutions and infrastructures, businesses, and other socio-economic actors. They are open to applicants from Europe and beyond.

- Call opens: 29 May 2024 • Deadline: 27 November 2024
- Budget: 451,15 M€



- I am planning to apply (this call) (33)
- I would be interested in participating, but in future calls (52)
- I am not planning to apply or I am not interested (39)

42%

I would be interested in participating, but in future calls

30%

I am not planning to apply or I am not interested


26%

I am planning to apply (this call)

## MSCA Postdoctoral Fellowships 2024

MSCA Postdoctoral Fellowships are open to excellent researchers of any nationality. They enhance the creative and innovative potential of researchers holding a PhD and who wish to acquire new skills and experience.

- Call opens: 10 April 2024 • Deadline: 11 September 2024
- Budget: 270.75 M€



- I am planning to apply (this call) (21)
- I would be interested in participating, but in future calls (50)
- I am not planning to apply or I am not interested (53)

42%

I am not planning to apply or I am not interested

40%

I would be interested in participating, but in future calls

17%

I am planning to apply (this call)



# Interest and/or potential fit in forthcoming calls


## MSCA International Cooperation 2024

Fosters international cooperation in MSCA in Horizon Europe, through a dedicated support action to complement and ensure coordination between existing promotion channels at local level, and ensure consistency with formal R&I policy dialogues at bilateral and regional levels.

- Call opens: 14 May 2024 • Deadline: 4 September 2024
- Budget: 2 M€



- I am planning to apply (this call) (9)
- I would be interested in participating, but in future calls (41)
- I am not planning to apply or I am not interested (74)







VALENCIA BIOMEDICAL  
RESEARCH FOUNDATION  
CENTRO DE INVESTIGACIÓN PRINCIPE FELIPE



Funded by  
the European Union

# MANY THANKS!



## PROTEOCURE

